1
|
Aguilar-Mahecha A, Alirezaie N, Lafleur J, Bareke E, Przybytkowski E, Lan C, Cavallone L, Salem M, Pelmus M, Aleynikova O, Greenwood C, Lovato A, Ferrario C, Boileau JF, Mihalcioiu C, Roy JA, Marcus E, Discepola F, Majewski J, Basik M. The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers. Genes (Basel) 2023; 15:27. [PMID: 38254917 PMCID: PMC10815241 DOI: 10.3390/genes15010027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Revised: 12/14/2023] [Accepted: 12/20/2023] [Indexed: 01/24/2024] Open
Abstract
The response of triple-negative breast cancer (TNBC) patients to pre-operative (neoadjuvant chemotherapy) is a critical factor of their outcome. To determine the effects of chemotherapy on the tumor genome and to identify mutations associated with chemoresistance and sensitivity, we performed whole exome sequencing on pre/post-chemotherapy tumors and matched lymphocytes from 26 patients. We observed great inter-tumoral heterogeneity with no gene mutated recurrently in more than four tumors besides TP53. Although the degree of response to chemotherapy in residual tumors was associated with more subclonal changes during chemotherapy, there was minimal evolution between pre/post-tumors. Indeed, gene sets enriched for mutations in pre- and post-chemotherapy tumors were very similar and reflected genes involved in the biological process of neurogenesis. Somatically mutated genes present in chemosensitive tumors included COL1A2, PRMD15, APOBEC3B, PALB2 and histone protein encoding genes, while BRCA1, ATR, ARID1A, XRCC3 and genes encoding for tubulin-associated proteins were present in the chemoresistant tumors. We also found that the mutational spectrum of post-chemotherapy tumors was more reflective of matching metastatic tumor biopsies than pre-chemotherapy samples. These findings support a portrait of modest ongoing genomic instability with respect to single-nucleotide variants induced by or selected for by chemotherapy in TNBCs.
Collapse
Affiliation(s)
- Adriana Aguilar-Mahecha
- Cancer Genomics and Translational Research Laboratory, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Najmeh Alirezaie
- Department of Human Genetics, McGill University, Montreal, QC H3A 1A4, Canada; (N.A.); (J.M.)
| | - Josiane Lafleur
- Cancer Genomics and Translational Research Laboratory, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Eric Bareke
- Department of Human Genetics, McGill University, Montreal, QC H3A 1A4, Canada; (N.A.); (J.M.)
| | - Ewa Przybytkowski
- Cancer Genomics and Translational Research Laboratory, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Cathy Lan
- Cancer Genomics and Translational Research Laboratory, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Luca Cavallone
- Cancer Genomics and Translational Research Laboratory, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Myriam Salem
- Cancer Genomics and Translational Research Laboratory, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Manuela Pelmus
- Department of Pathology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Olga Aleynikova
- Department of Pathology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Celia Greenwood
- Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada; (C.G.)
| | - Amanda Lovato
- Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada; (C.G.)
| | - Cristiano Ferrario
- Department of Oncology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | | | | | - Josée-Anne Roy
- Hôpital du Sacré-Cœur de Montréal, Montreal, QC H4J 1C5, Canada;
| | | | - Federico Discepola
- Department of Radiology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Jacek Majewski
- Department of Human Genetics, McGill University, Montreal, QC H3A 1A4, Canada; (N.A.); (J.M.)
| | - Mark Basik
- Cancer Genomics and Translational Research Laboratory, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
- Department of Oncology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
- McGill University Health Center, Montreal, QC H3A 3J1, Canada
| |
Collapse
|
2
|
Roseshter T, Klemantovich A, Cavallone L, Aguilar-Mahecha A, Lafleur J, Elebute OO, Jenna S, Boileau JF, Pelmus M, Basik M, Lan C. Abstract P2-11-26: The prognostic role of circulating tumor DNA after neoadjuvant chemotherapy in triple negative breast cancer with residual tumor. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p2-11-26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Background The presence of residual tumour at surgery (non-pathological complete response or non-pCR) occurs in about half of TNBCs treated with neoadjuvant chemotherapy (NAC) and signals chemoresistance and poor prognosis. Although further adjuvant chemotherapy (Capecitabine/Xeloda) results in improved survival in patients with non-pCR, only about 15% of such patients do benefit. Circulating tumor DNA (ctDNA) is a plasma-based biomarker that can be used to reveal real-time data about the disease and treatment progression. We have previously shown that detection of ctDNA after NAC signals poor prognosis. To validate and extend our previous results using an academic hospital-based tumor bespoke assay, we performed ctDNA measurements in non-pCR TNBC patients at the pre-operative, post-operative, 3 and 6-month time points. Methods Whole exome sequencing (WES) was performed on residual tumors from 34 TNBC patients to identify tumour-specific mutations (5/patient). Digital droplet PCR (ddPCR) assays were developed for these mutations and performed as per our previous work. Patients with at least one detectable mutation were considered ctDNA positive for a given time point. The detection of ctDNA was correlated with relapse-free survival (RFS). Results The overall RFS was 44%, with 56 % of patients received adjuvant Xeloda. Detection of ctDNA at the end of NAC (T1) correlated with poor prognosis of RFS (n = 33, p-value = 0.009, HR = 0.29 (95% CI = 0.12 to 0.74)). Detection of ctDNA after surgery (T2) and while on Xeloda (T3) showed no significant prognostic value for RFS. However, ctDNA detection at the 6-month time point, after Xeloda treatment (T4), showed stronger prognostic value for RFS (n = 17, p-value = 0.004, HR = 0.12 (95% CI = 0.03 to 0.51)). When measuring changes in ctDNA detectability from T1 to T4, 4 patients initially positive became ctDNA negative after the 6-month interval, and only 1 of these 4 had a relapse, compared with 10 of 11 that remained positive at the 6-month time point (p = 0.01, Chi-squared test). 3 of the 4 patients that cleared their ctDNA had received Xeloda. In addition, 2 patients initially negative became ctDNA positive at the 6-month time point (T4) and both relapsed, compared with only 1 of 5 that remained negative at 6 months (p = 0.035, Chi-squared test). For patients who received adjuvant Xeloda ctDNA positivity at T1 was associated with a worse RFS (p-value = 0.028, HR = 3.3884 (95% CI = 1.160 to 13.00)). Conclusion ctDNA testing using ddPCR in an academic hospital-based context at the post-NAC time point as well as at 6 months after surgery identifies an excellent prognostic group in TNBC patients with non-pCR and changes in ctDNA during the adjuvant period have prognostic value. This personalized approach to treatment management is ready for prospective testing in patients who have undergone NAC and require additional chemotherapy.
Citation Format: Talia Roseshter, Anna Klemantovich, Luca Cavallone, Adriana Aguilar-Mahecha, Josiane Lafleur, Oluwadara O. Elebute, Sarah Jenna, Jean-Francois Boileau, Manuela Pelmus, Mark Basik, Cathy Lan. The prognostic role of circulating tumor DNA after neoadjuvant chemotherapy in triple negative breast cancer with residual tumor [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P2-11-26.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Manuela Pelmus
- 9Jewish General Hospital Segal Cancer Centre, McGill University, Montréal, Quebec, Canada
| | | | - Cathy Lan
- 11Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
| |
Collapse
|
3
|
Biswas K, Couillard M, Cavallone L, Burkett S, Stauffer S, Martin BK, Southon E, Reid S, Plona TM, Baugher RN, Mellott SD, Pike KM, Albaugh ME, Maedler-Kron C, Hamel N, Tessarollo L, Marcus V, Foulkes WD, Sharan SK. A novel mouse model of PMS2 founder mutation that causes mismatch repair defect due to aberrant splicing. Cell Death Dis 2021; 12:838. [PMID: 34489406 PMCID: PMC8421400 DOI: 10.1038/s41419-021-04130-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 08/10/2021] [Accepted: 08/18/2021] [Indexed: 11/09/2022]
Abstract
Hereditary non-polyposis colorectal cancer, now known as Lynch syndrome (LS) is one of the most common cancer predisposition syndromes and is caused by germline pathogenic variants (GPVs) in DNA mismatch repair (MMR) genes. A common founder GPV in PMS2 in the Canadian Inuit population, NM_000535.5: c.2002A>G, leads to a benign missense (p.I668V) but also acts as a de novo splice site that creates a 5 bp deletion resulting in a truncated protein (p.I668*). Individuals homozygous for this GPV are predisposed to atypical constitutional MMR deficiency with a delayed onset of first primary malignancy. We have generated mice with an equivalent germline mutation (Pms2c.1993A>G) and demonstrate that it results in a splicing defect similar to those observed in humans. Homozygous mutant mice are viable like the Pms2 null mice. However, unlike the Pms2 null mice, these mutant mice are fertile, like humans homozygous for this variant. Furthermore, these mice exhibit a significant increase in microsatellite instability and intestinal adenomas on an Apc mutant background. Rectification of the splicing defect in human and murine fibroblasts using antisense morpholinos suggests that this novel mouse model can be valuable in evaluating the efficacy aimed at targeting the splicing defect in PMS2 that is highly prevalent among the Canadian Inuits.
Collapse
Affiliation(s)
- Kajal Biswas
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Martin Couillard
- The Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC, Canada
| | - Luca Cavallone
- The Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC, Canada
| | - Sandra Burkett
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Stacey Stauffer
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Betty K Martin
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
- Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA
| | - Eileen Southon
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
- Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA
| | - Susan Reid
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Teri M Plona
- CLIA Molecular Diagnostics Laboratory, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Ryan N Baugher
- CLIA Molecular Diagnostics Laboratory, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Stephanie D Mellott
- CLIA Molecular Diagnostics Laboratory, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Kristen M Pike
- CLIA Molecular Diagnostics Laboratory, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Mary E Albaugh
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
- Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA
| | | | - Nancy Hamel
- Department of Oncology, McGill University, Montreal, QC, Canada
- Department of Human Genetics, McGill University, Montreal, QC, Canada
| | - Lino Tessarollo
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Victoria Marcus
- Department of Pathology, McGill University, Montreal, QC, Canada
| | - William D Foulkes
- The Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC, Canada
- Department of Oncology, McGill University, Montreal, QC, Canada
- Department of Human Genetics, McGill University, Montreal, QC, Canada
- Department of Medical Genetics, Jewish General Hospital, McGill University, Montreal, QC, H3T 1E2, Canada
- Department of Medical Genetics and Cancer Research Program, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, H4A 3JI, Canada
| | - Shyam K Sharan
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
| |
Collapse
|
4
|
Cavallone L, Aguilar-Mahecha A, Lafleur J, Brousse S, Aldamry M, Roseshter T, Lan C, Alirezaie N, Bareke E, Majewski J, Ferrario C, Hassan S, Discepola F, Seguin C, Mihalcioiu C, Marcus EA, Robidoux A, Roy JA, Pelmus M, Basik M. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci Rep 2020; 10:14704. [PMID: 32895401 PMCID: PMC7477566 DOI: 10.1038/s41598-020-71236-y] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Accepted: 08/03/2020] [Indexed: 01/09/2023] Open
Abstract
Response to neoadjuvant chemotherapy (NAC) in triple negative breast cancer (TNBC) is highly prognostic and determines whether adjuvant chemotherapy is needed if residual tumor is found at surgery. To evaluate the predictive and prognostic values of circulating tumor DNA (ctDNA) in this setting, we analyzed tumor and serial bloods from 26 TNBC patients collected prior, during, and after NAC. Individual digital droplet PCR assays were developed for 121 variants (average 5/patient) identified from tumor sequencing, enabling ctDNA detection in 96% of patients at baseline. Mutant allele frequency at baseline was associated with clinical characteristics. Levels drastically fell after one cycle of NAC, especially in patients whose tumors would go on to have a pathological complete response (pCR), but then rose significantly before surgery in patients with significant residual tumor at surgery (p = 0.0001). The detection of ctDNA early during treatment and also late at the end of NAC before surgery was strongly predictive of residual tumor at surgery, but its absence was less predictive of pCR, especially when only TP53 variants are considered. ctDNA detection at the end of neoadjuvant chemotherapy indicated significantly worse relapse-free survival (HR = 0.29 (95% CI 0.08–0.98), p = 0.046), and overall survival (HR = 0.27 95% CI 0.075–0.96), p = 0.043). Hence, individualized multi-variant ctDNA testing during and after NAC prior to surgery has prognostic and predictive value in early TNBC patients.
Collapse
Affiliation(s)
- Luca Cavallone
- Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada
| | | | - Josiane Lafleur
- Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada
| | - Susie Brousse
- Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada
| | - Mohammed Aldamry
- Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada
| | - Talia Roseshter
- Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada
| | - Cathy Lan
- Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada
| | - Najmeh Alirezaie
- Department of Human Genetics, McGill University, Montreal, QC, Canada
| | - Eric Bareke
- Department of Human Genetics, McGill University, Montreal, QC, Canada
| | - Jacek Majewski
- Department of Human Genetics, McGill University, Montreal, QC, Canada
| | | | - Saima Hassan
- Division of Surgical Oncology, Department of Surgery, Centre Hospitalier de L'Université de Montréal (CHUM), Montreal, QC, Canada
| | | | - Carole Seguin
- Department of Radiology, Jewish General Hospital, Montreal, QC, Canada
| | | | | | - André Robidoux
- Division of Surgical Oncology, Department of Surgery, Centre Hospitalier de L'Université de Montréal (CHUM), Montreal, QC, Canada
| | | | - Manuela Pelmus
- Department of Pathology, Jewish General Hospital, Montreal, QC, Canada
| | - Mark Basik
- Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
| |
Collapse
|
5
|
Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalcioiu C, Majewski J, Basik M. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability. Mol Cancer Res 2019; 17:2492-2507. [PMID: 31537618 DOI: 10.1158/1541-7786.mcr-19-0264] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2019] [Revised: 06/18/2019] [Accepted: 09/16/2019] [Indexed: 11/16/2022]
Abstract
The major obstacle in successfully treating triple-negative breast cancer (TNBC) is resistance to cytotoxic chemotherapy, the mainstay of treatment in this disease. Previous preclinical models of chemoresistance in TNBC have suffered from a lack of clinical relevance. Using a single high dose chemotherapy treatment, we developed a novel MDA-MB-436 cell-based model of chemoresistance characterized by a unique and complex morphologic phenotype, which consists of polyploid giant cancer cells giving rise to neuron-like mononuclear daughter cells filled with smaller but functional mitochondria and numerous lipid droplets. This resistant phenotype is associated with metabolic reprogramming with a shift to a greater dependence on fatty acids and oxidative phosphorylation. We validated both the molecular and histologic features of this model in a clinical cohort of primary chemoresistant TNBCs and identified several metabolic vulnerabilities including a dependence on PLIN4, a perilipin coating the observed lipid droplets, expressed both in the TNBC-resistant cells and clinical chemoresistant tumors treated with neoadjuvant doxorubicin-based chemotherapy. These findings thus reveal a novel mechanism of chemotherapy resistance that has therapeutic implications in the treatment of drug-resistant cancer. IMPLICATIONS: These findings underlie the importance of a novel morphologic-metabolic phenotype associated with chemotherapy resistance in TNBC, and bring to light novel therapeutic targets resulting from vulnerabilities in this phenotype, including the expression of PLIN4 essential for stabilizing lipid droplets in resistant cells.
Collapse
Affiliation(s)
- Isabelle Sirois
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Division of Experimental Medicine, McGill University, Montréal, Québec, Canada
| | - Adriana Aguilar-Mahecha
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Josiane Lafleur
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Emma Fowler
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Division of Experimental Medicine, McGill University, Montréal, Québec, Canada
| | - Viet Vu
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Michelle Scriver
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Marguerite Buchanan
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Catherine Chabot
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Aparna Ramanathan
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Banujan Balachandran
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Division of Experimental Medicine, McGill University, Montréal, Québec, Canada
| | - Stéphanie Légaré
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Division of Experimental Medicine, McGill University, Montréal, Québec, Canada
| | - Ewa Przybytkowski
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Cathy Lan
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Urszula Krzemien
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Luca Cavallone
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Olga Aleynikova
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Department of Oncology and Surgery, McGill University, Montréal, Québec, Canada
| | - Cristiano Ferrario
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Department of Oncology and Surgery, McGill University, Montréal, Québec, Canada
| | - Marie-Christine Guilbert
- Hôpital Maisonneuve Rosemont, Département de pathologie et biologie cellulaire, Université de Montréal, Québec, Canada
| | - Naciba Benlimame
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Amine Saad
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.,Department of Oncology and Surgery, McGill University, Montréal, Québec, Canada
| | - Moulay Alaoui-Jamali
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.,Department of Oncology and Surgery, McGill University, Montréal, Québec, Canada
| | - Horace Uri Saragovi
- Lady Davis Institute-Jewish General Hospital; Center for Translational Research, McGill University, Montréal, Québec, Canada.,Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada.,Integrated Program for Neuroscience, McGill University, Montréal, Québec, Canada
| | - Sylvia Josephy
- Lady Davis Institute-Jewish General Hospital; Center for Translational Research, McGill University, Montréal, Québec, Canada.,Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada.,Integrated Program for Neuroscience, McGill University, Montréal, Québec, Canada
| | - Ciara O'Flanagan
- Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Stephen D Hursting
- Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.,University of North Carolina Nutrition Research Institute, Kannapolis, North Carolina
| | - Vincent R Richard
- Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - René P Zahedi
- Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Gerald Bronfman Department of Oncology, Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Christoph H Borchers
- Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.,Gerald Bronfman Department of Oncology, Jewish General Hospital, McGill University, Montréal, Québec, Canada.,University of Victoria Genome British Columbia Proteomics Centre, University of Victoria, Victoria, Canada
| | - Eric Bareke
- McGill University and Genome Québec Innovation Center, Montréal, Québec, Canada
| | - Sheida Nabavi
- Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts
| | - Peter Tonellato
- Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts
| | | | - André Robidoux
- Centre Hospitalier de l'Université de Montreal, Montreal, Québec, Canada
| | | | | | - Jacek Majewski
- McGill University and Genome Québec Innovation Center, Montréal, Québec, Canada.,Department of Human Genetics, McGill University, Montréal, Québec, Canada
| | - Mark Basik
- Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada. .,Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.,Department of Oncology and Surgery, McGill University, Montréal, Québec, Canada
| |
Collapse
|
6
|
Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L, Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, Foulkes WD, Reis-Filho JS. Homologous recombination DNA repair defects in PALB2-associated breast cancers. NPJ Breast Cancer 2019; 5:23. [PMID: 31428676 PMCID: PMC6687719 DOI: 10.1038/s41523-019-0115-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Accepted: 06/04/2019] [Indexed: 01/02/2023] Open
Abstract
Mono-allelic germline pathogenic variants in the Partner And Localizer of BRCA2 (PALB2) gene predispose to a high-risk of breast cancer development, consistent with the role of PALB2 in homologous recombination (HR) DNA repair. Here, we sought to define the repertoire of somatic genetic alterations in PALB2-associated breast cancers (BCs), and whether PALB2-associated BCs display bi-allelic inactivation of PALB2 and/or genomic features of HR-deficiency (HRD). Twenty-four breast cancer patients with pathogenic PALB2 germline mutations were analyzed by whole-exome sequencing (WES, n = 16) or targeted capture massively parallel sequencing (410 cancer genes, n = 8). Somatic genetic alterations, loss of heterozygosity (LOH) of the PALB2 wild-type allele, large-scale state transitions (LSTs) and mutational signatures were defined. PALB2-associated BCs were found to be heterogeneous at the genetic level, with PIK3CA (29%), PALB2 (21%), TP53 (21%), and NOTCH3 (17%) being the genes most frequently affected by somatic mutations. Bi-allelic PALB2 inactivation was found in 16 of the 24 cases (67%), either through LOH (n = 11) or second somatic mutations (n = 5) of the wild-type allele. High LST scores were found in all 12 PALB2-associated BCs with bi-allelic PALB2 inactivation sequenced by WES, of which eight displayed the HRD-related mutational signature 3. In addition, bi-allelic inactivation of PALB2 was significantly associated with high LST scores. Our findings suggest that the identification of bi-allelic PALB2 inactivation in PALB2-associated BCs is required for the personalization of HR-directed therapies, such as platinum salts and/or PARP inhibitors, as the vast majority of PALB2-associated BCs without PALB2 bi-allelic inactivation lack genomic features of HRD.
Collapse
Affiliation(s)
- Anqi Li
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
- Department of Pathology, Fudan University Shanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai, P.R. China
| | - Felipe C. Geyer
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Pedro Blecua
- Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Ju Youn Lee
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Pier Selenica
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - David N. Brown
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Fresia Pareja
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Simon S. K. Lee
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Rahul Kumar
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Barbara Rivera
- Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec Canada
- Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec Canada
| | - Rui Bi
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
- Department of Pathology, Fudan University Shanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai, P.R. China
| | - Salvatore Piscuoglio
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - Hannah Y. Wen
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - John R. Lozada
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | | | - Luca Cavallone
- Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec Canada
- Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec Canada
| | - Zoulikha Rezoug
- Cancer Prevention Center, Jewish General Hospital, Montreal, Quebec Canada
| | - Tu Nguyen-Dumont
- Genetic Epidemiology Laboratory, Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia
| | - Paolo Peterlongo
- IFOM, The Italian Foundation for Cancer Research Institute of Molecular Oncology, Milan, Italy
| | | | - Thorkild Terkelsen
- Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark
| | - Karina Rønlund
- Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark
| | - Susanne E. Boonen
- Clinical Genetics Unit, Department of Pediatrics, Zealand University Hospital, Roskilde, Denmark
| | - Arto Mannerma
- Biocenter Kuopio and Cancer Center of Easter Finland, University of Eastern Finland, Kuopio, Finland
| | - Robert Winqvist
- Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland
| | - Marketa Janatova
- Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | | | - Bing Xia
- Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ USA
| | - Larry Norton
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Mark E. Robson
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Pei-Sze Ng
- Cancer Research Malaysia, Subang Jaya, Malaysia
| | - Lai-Meng Looi
- Department of Pathology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
| | - Melissa C. Southey
- Genetic Epidemiology Laboratory, Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia
| | - Britta Weigelt
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Teo Soo-Hwang
- Cancer Research Malaysia, Subang Jaya, Malaysia
- University Malaya Cancer Research Institute, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
| | - Marc Tischkowitz
- Department of Medical Genetics, University of Cambridge, Cambridge, UK
| | - William D. Foulkes
- Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec Canada
- Cancer Prevention Center, Jewish General Hospital, Montreal, Quebec Canada
- Cancer Program, Research Institute McGill University Health Centre, Montreal, Quebec Canada
| | - Jorge S. Reis-Filho
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
| |
Collapse
|
7
|
Aguilar-Mahecha A, Joseph S, Cavallone L, Buchanan M, Krzemien U, Batist G, Basik M. Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report. Front Oncol 2019; 9:698. [PMID: 31448226 PMCID: PMC6691136 DOI: 10.3389/fonc.2019.00698] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Accepted: 07/15/2019] [Indexed: 12/18/2022] Open
Abstract
Trastuzumab, has played a major role in improving treatment outcomes in HER-2 positive gastric cancer. However, once there is disease progression there is a paucity of evidence for second line therapy. Patient-derived xenografts (PDXs) in combination with liquid biopsies can help guide individual therapeutic decisions and have now started to be studied. In the present case we established a PDX model from a metastatic HER-2+ gastric cancer patient and after the first engraftment passage we performed a mouse clinical trial to test T-DM1 as an alternative therapy for the patient. The PDX tumor response served as a guide to administer T-DM1 therapy to the patient who responded to treatment before relapsing 6 months later. Throughout out the clinical follow up of the patient, ctDNA levels of HER-2 copy number and a PIK3CA mutation were monitored and we found their correlation with drug response and disease progression to outperform that of CEA levels. This study highlights the utility of applying precision medicine tools combining PDX models to guide therapy with circulating tumor DNA (ctDNA) to monitor treatment response and disease progression.
Collapse
Affiliation(s)
| | - Sarah Joseph
- Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada
| | - Luca Cavallone
- Department of Oncology, Lady Davis Institute, McGill University, Montreal, QC, Canada
| | - Marguerite Buchanan
- Department of Oncology, Lady Davis Institute, McGill University, Montreal, QC, Canada
| | - Urszula Krzemien
- Department of Oncology, Lady Davis Institute, McGill University, Montreal, QC, Canada
| | - Gerald Batist
- Department of Oncology, Lady Davis Institute, McGill University, Montreal, QC, Canada.,Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada
| | - Mark Basik
- Department of Oncology, Lady Davis Institute, McGill University, Montreal, QC, Canada.,Department of Surgery, Jewish General Hospital, Montreal, QC, Canada
| |
Collapse
|
8
|
Cavallone L, Aguilar A, Aldamry M, Lafleur J, Brousse S, Lan C, Alirezaie N, Bareke E, Majewski J, Pelmus M, Ferrario C, Marcus EA, Robidoux A, Discepola F, Basik M. Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TNBC). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.594] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
594 Background: TNBC, the most aggressive form of breast cancer, is treated primarily with chemotherapy, even before surgery (neoadjuvant chemotherapy or NAC). The prognosis and need for adjuvant therapy depends greatly on the tumor response assessed by pathology (pCR). Highly sensitive and specific ctDNA assays have been shown to be of prognostic value in the metastatic settingbut not yet in earlier settings. Methods: Tissue was collected from 26 Q-CROC-03 clinical trial TNBC patients before, during and after NAC, prior to surgery. Whole exome sequencing on tumor tissues was used to select single nucleotide variants with high allele frequency (VAF), prioritizing TP53, to generateindividual digital droplet PCR (ddPCR) assays. An average of 5 variants (range 1-12) per patient were tested, for a total of 121 variants. A detection threshold was defined for each variant from a pool of normal controls. Median follow-up was 55 months. Results: ctDNA was detectable in 96% of patients at baseline, but 20% of the 121 variants were not detectable at any time point. At baseline, the mean VAF of all analyzed variants, but not of TP53 variants alone, was significantly correlated (p < 0.05) with tumor factors (tumor size, stage, grade, nodal status before and at surgery, RCB score) but not with patient age or BRCA1/2 mutation status. 87 variants (74%) were detected at baseline and their VAF fell by 86% after 1 cycle of chemotherapy (T1). The detection of ctDNA at T1 was associated with DFS (p = 0.027) while the detection of ctDNA at the last post-chemotherapy pre-surgery time point (T4) was strongly associated with pathological complete response (pCR) and both DFS (p = 0.013) and OS(p = 0.006). At this time point, 5 of 41 variants (12%) were detected in pCR patients vs 42 of 80 (53%) in non-pCR, while only 6 of the 15 (40%) non-pCR patients had detectable TP53 variants. Interestingly, for variants detected at baseline, the positive predictive value of T4 ctDNA for disease recurrence was 69%, similar to that of non-pCR, while the negative predictive value of no ctDNA at T4 was 89% for disease recurrence vs 80% for pCR. Conclusions: ctDNA detection after NAC prior to surgery is strongly predictive of disease-free survival and overall survival and is comparable to pCR as a prognostic factor in our cohort (NCT01276899).
Collapse
Affiliation(s)
- Luca Cavallone
- Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
| | - Adriana Aguilar
- Segal Cancer Centre/Jewish General Hospital and McGill University, Montreal, QC, Canada
| | - Mohammed Aldamry
- Jewish General Hospital, Lady Davis Institute/Segal Cancer Center, Montreal, QC, Canada
| | - Josiane Lafleur
- Segal Cancer Center/Jewish General Hospital, Montreal, QC, Canada
| | | | - Cathy Lan
- Jewish General Hospital, Lady Davis Institute/Segal Cancer Center, Montreal, QC, Canada
| | - Najmeh Alirezaie
- Department of Human Genetics, McGill University, Montreal, QC, Canada
| | - Eric Bareke
- Department of Human Genetics, McGill University, Montreal, QC, Canada
| | - Jacek Majewski
- Department of Human Genetics, McGill University, Montreal, QC, Canada
| | | | | | | | - Andre Robidoux
- Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
| | | | - Mark Basik
- Segal Cancer Center, Montreal, QC, Canada
| |
Collapse
|
9
|
Cavallone L, Adriana AM, Aldamry M, Lafleur J, Cathy L, Alirezaie N, Bareke E, Majewski J, Ferrario C, Mihalciou C, Roy JA, Markus E, Robidoux A, Pelmus M, Aleynikova O, Discepola F, Basik M. Abstract P2-02-02: Dynamics of ctDNA changes during neoadjuvant chemotherapy in triple-negative breast cancer patients. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-02-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Liquid biopsies to monitor response to treatment are a minimally invasive and highly attractive method for clinical application. Detection of ctDNA in plasma is now highly sensitive thanks to the use of novel highly sensitive and specific techniques such as ddPCR. In the present study we set out to analyze the utility of using ctDNA to monitor response to treatment in patients receiving standard neoadjuvant chemotherapy in triple negative breast cancer.
Methods:
Serial blood was collected from triple negative breast cancer patients participating in the Q-CROC-03 clinical trial (NCT01276899). The trial recruited triple negative breast cancer patients undergoing standard neoadjuvant chemotherapy. Paired biopsies were collected prior and at the end of treatment and serial bloods collected throughout the study. Whole exome sequencing was performed on tissues collected and we identified mutated genes of interest. Cell free DNA (cfDNA) was extracted from 3 ml of plasma and 4-10 variants per patient were analyzed by ddPCR in serial plasma samples collected before and during treatment. Response was measured by evaluating residual cancer burden (RCB), and non-responders were RCBII-III, responders RCB0-I.
Results:
For the present analysis, we identified 60 variants in tumors from 12 patients (9 RCBII-III and 3 RCB0-I). Except for TP53, none of the genes were shared among the tumors. 20% of the variants were not detected in ctDNA at any time point and we did not find any correlation between cfDNA levels and tumor size or response to treatment. The average variant allele frequency (VAF) of all detected variants at baseline was higher in RCBII-III patients than in RCB0-I patients (7.0 vs 0.7 respectively). Interestingly, variants that were detected either only in the pre-chemo tumor or in the post-chemo tumor were frequently detected throughout neoadjuvant therapy, highlighting the ability of ctDNA to capture tumor heterogeneity. In almost all cases, we observed a dramatic decrease in ctDNA VAF after one cycle of chemotherapy, including 30% to non-detectable levels. By the 5th cycle of chemotherapy 97% of detected variants had decreased (average 95% decrease). This decrease in ctDNA VAF was independent of RCB score. In some RCBII-III cases, ctDNA VAF increased prior to surgery, reflecting residual tumor presence.
Conclusion:
ctDNA could be detected in plasma of all early TNBC patients undergoing neoadjuvant chemotherapy with the majority of variants detected in plasma collected at baseline prior to chemotherapy. Once treatment started, the abundance of ctDNA markedly decreased in plasma independently of tumor response. The effect of chemotherapy on levels of ctDNA needs further investigation.
Citation Format: Cavallone L, Adriana A-M, Aldamry M, Lafleur J, Cathy L, Alirezaie N, Bareke E, Majewski J, Ferrario C, Mihalciou C, Roy J-A, Markus E, Robidoux A, Pelmus M, Aleynikova O, Discepola F, Basik M. Dynamics of ctDNA changes during neoadjuvant chemotherapy in triple-negative breast cancer patients [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-02-02.
Collapse
Affiliation(s)
- L Cavallone
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - A-M Adriana
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - M Aldamry
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - J Lafleur
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - L Cathy
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - N Alirezaie
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - E Bareke
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - J Majewski
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - C Ferrario
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - C Mihalciou
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - J-A Roy
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - E Markus
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - A Robidoux
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - M Pelmus
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - O Aleynikova
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - F Discepola
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - M Basik
- Lady Davis Institute for Medical Research, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Hopital Sacre Coeur, Montreal, QC, Canada; John H. Stroger Jr. Hospital, Chicago, IL; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| |
Collapse
|
10
|
Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, Basik M, Johnson NA, Deyell RJ, Rassekh SR, Morin RD. Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. Sci Rep 2017; 7:10574. [PMID: 28874686 PMCID: PMC5585219 DOI: 10.1038/s41598-017-10269-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Accepted: 08/02/2017] [Indexed: 12/12/2022] Open
Abstract
Ultrasensitive methods for rare allele detection are critical to leverage the full potential offered by liquid biopsies. Here, we describe a novel molecular barcoding method for the precise detection and quantification of circulating tumor DNA (ctDNA). The major benefits of our design include straightforward and cost-effective production of barcoded adapters to tag individual DNA molecules before PCR and sequencing, and better control over cross-contamination between experiments. We validated our approach in a cohort of 24 patients with a broad spectrum of cancer diagnoses by targeting and quantifying single-nucleotide variants (SNVs), indels and genomic rearrangements in plasma samples. By using personalized panels targeting a priori known mutations, we demonstrate comprehensive error-suppression capabilities for SNVs and detection thresholds for ctDNA below 0.1%. We also show that our semi-degenerate barcoded adapters hold promise for noninvasive genotyping in the absence of tumor biopsies and monitoring of minimal residual disease in longitudinal plasma samples. The benefits demonstrated here include broad applicability, flexibility, affordability and reproducibility in the research and clinical settings.
Collapse
Affiliation(s)
- Miguel Alcaide
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
| | - Stephen Yu
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
| | - Jordan Davidson
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
| | - Marco Albuquerque
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
| | - Kevin Bushell
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
| | - Daniel Fornika
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
| | - Sarah Arthur
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
| | - Bruno M Grande
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
| | - Suzan McNamara
- Quebec Clinical Research Organization in Cancer (Q-CROC), Exactis Innovation and the Segal Cancer Centre, Montreal, QC, Canada
| | - Mathilde Couetoux du Tertre
- Quebec Clinical Research Organization in Cancer (Q-CROC), Exactis Innovation and the Segal Cancer Centre, Montreal, QC, Canada
| | - Gerald Batist
- Quebec Clinical Research Organization in Cancer (Q-CROC), Exactis Innovation and the Segal Cancer Centre, Montreal, QC, Canada
| | - David G Huntsman
- Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.,Department of Pathology and Laboratory Medicine and Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
| | - Luca Cavallone
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada
| | - Adriana Aguilar
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada
| | - Mark Basik
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada
| | - Nathalie A Johnson
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada
| | - Rebecca J Deyell
- Division of Oncology, Hematology and Bone Marrow Transplant, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
| | - S Rod Rassekh
- Division of Oncology, Hematology and Bone Marrow Transplant, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
| | - Ryan D Morin
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
| |
Collapse
|
11
|
Légaré S, Cavallone L, Mamo A, Chabot C, Sirois I, Magliocco A, Klimowicz A, Tonin PN, Buchanan M, Keilty D, Hassan S, Laperrière D, Mader S, Aleynikova O, Basik M. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers. Cancer Res 2015; 75:4351-63. [PMID: 26297734 DOI: 10.1158/0008-5472.can-14-3475] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2014] [Accepted: 07/10/2015] [Indexed: 11/16/2022]
Abstract
The treatment of breast cancer has benefitted tremendously from the generation of estrogen receptor-α (ERα)-targeted therapies, but disease relapse continues to pose a challenge due to intrinsic or acquired drug resistance. In an effort to delineate potential predictive biomarkers of therapy responsiveness, multiple groups have identified several uncharacterized cofactors and interacting partners of ERα, including Split Ends (SPEN), a transcriptional corepressor. Here, we demonstrate a role for SPEN in ERα-expressing breast cancers. SPEN nonsense mutations were detectable in the ERα-expressing breast cancer cell line T47D and corresponded to undetectable protein levels. Further analysis of 101 primary breast tumors revealed that 23% displayed loss of heterozygosity at the SPEN locus and that 3% to 4% harbored somatically acquired mutations. A combination of in vitro and in vivo functional assays with microarray-based pathway analyses showed that SPEN functions as a tumor suppressor to regulate cell proliferation, tumor growth, and survival. We also found that SPEN binds ERα in a ligand-independent manner and negatively regulates the transcription of ERα targets. Moreover, we demonstrate that SPEN overexpression sensitizes hormone receptor-positive breast cancer cells to the apoptotic effects of tamoxifen, but has no effect on responsiveness to fulvestrant. Consistent with these findings, two independent datasets revealed that high SPEN protein and RNA expression in ERα-positive breast tumors predicted favorable outcome in patients treated with tamoxifen alone. Together, our data suggest that SPEN is a novel tumor-suppressor gene that may be clinically useful as a predictive biomarker of tamoxifen response in ERα-positive breast cancers.
Collapse
Affiliation(s)
- Stéphanie Légaré
- Department of Surgery and Oncology, McGill University, Montréal, Québec, Canada. Department of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada
| | - Luca Cavallone
- Department of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada
| | - Aline Mamo
- Department of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada
| | - Catherine Chabot
- Department of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada
| | - Isabelle Sirois
- Department of Surgery and Oncology, McGill University, Montréal, Québec, Canada. Department of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada
| | - Anthony Magliocco
- Department of Pathology, University of Calgary, Calgary, Alberta, Canada
| | | | - Patricia N Tonin
- Department of Human Genetics, McGill University and The Research Institute of the McGill University Health Centre, Montréal, Québec, Canada. Department of Medicine, McGill University and The Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
| | - Marguerite Buchanan
- Department of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada
| | - Dana Keilty
- Department of Surgery and Oncology, McGill University, Montréal, Québec, Canada. Department of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada
| | - Saima Hassan
- Department of Surgery and Oncology, McGill University, Montréal, Québec, Canada. Department of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada
| | - David Laperrière
- Institut de recherche en immunologie et cancérologie, IRIC, Montréal, Québec, Canada
| | - Sylvie Mader
- Institut de recherche en immunologie et cancérologie, IRIC, Montréal, Québec, Canada. Department de Biochimie, Université de Montréal, Montréal, Québec, Canada
| | - Olga Aleynikova
- Department of Pathology, Jewish General Hospital, Montréal, Quebec, Canada
| | - Mark Basik
- Department of Surgery and Oncology, McGill University, Montréal, Québec, Canada. Department of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada.
| |
Collapse
|
12
|
Hartley T, Cavallone L, Sabbaghian N, Silva-Smith R, Hamel N, Aleynikova O, Smith E, Hastings V, Pinto P, Tischkowitz M, Tomiak E, Foulkes WD. Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada. Hered Cancer Clin Pract 2014; 12:19. [PMID: 25225577 PMCID: PMC4163678 DOI: 10.1186/1897-4287-12-19] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2014] [Accepted: 08/14/2014] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND PALB2 has emerged as a breast cancer susceptibility gene. Mutations in PALB2 have been identified in almost all breast cancer populations studied to date, but the rarity of these mutations and lack of information regarding their penetrance makes genetic counseling for these families challenging. We studied BRCA1/2 -negative breast and/or ovarian cancer families to a) assess the contribution of PALB2 mutations in this series and b) identify clinical, pathological and family history characteristics that might make PALB2 screening more efficient. METHODS The coding region of the PALB2 gene was analyzed in 175 probands with family histories of breast and/or ovarian cancer ascertained from a single Canadian institution in Eastern Ontario. RESULTS We identified 2 probands with PALB2 mutations that are known or strongly considered to be pathogenic and 3 probands with missense mutations that are possibly pathogenic. One of the identified truncating mutations [c.3113G > A (p.Gly1000_Trp1038del - major product)], has been previously described while the other four mutations [c.3507_3508delTC (p.H1170Ffs*19), c.1846G > C (p.D616H), c.3418 T > G (p.W1140G), c.3287A > G (p.N1096S)] have not been previously reported. Loss of heterozygosity was detected in two breast tumors from one c.3507_3508delTC mutation carrier but not in other available tumors from that family or in tumors from carriers of other mutations. CONCLUSIONS PALB2 mutation screening identifies a small, but significant number of mutations in BRCA1/2 -negative breast and/or ovarian cancer families. We show that mutations are more likely to be found in families with three or more breast cancers as well as other BRCA2-related cancers. In our cohort, both clearly pathogenic mutations were identified in premenopausal breast cancer cases (2/77, 2.6%). Testing should be preferentially offered to affected women from such families.
Collapse
Affiliation(s)
- Taila Hartley
- Department of Genetics, Children's Hospital of Eastern Ontario, 401 Smyth Rd, K1H 8 L1 Ottawa, ON, Canada
| | - Luca Cavallone
- Program in Cancer Genetics, Departments of Oncology and Human Genetics, Gerald Bronfman Centre for Clinical Research in Oncology, McGill University, Montreal, QC, Canada ; Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada
| | - Nelly Sabbaghian
- Program in Cancer Genetics, Departments of Oncology and Human Genetics, Gerald Bronfman Centre for Clinical Research in Oncology, McGill University, Montreal, QC, Canada ; Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada
| | - Rachel Silva-Smith
- Program in Cancer Genetics, Departments of Oncology and Human Genetics, Gerald Bronfman Centre for Clinical Research in Oncology, McGill University, Montreal, QC, Canada ; Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada
| | - Nancy Hamel
- Program in Cancer Genetics, Departments of Oncology and Human Genetics, Gerald Bronfman Centre for Clinical Research in Oncology, McGill University, Montreal, QC, Canada ; Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada
| | - Olga Aleynikova
- Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada ; Department of Pathology, McGill University, Montreal, QC, Canada
| | - Erika Smith
- Department of Genetics, Children's Hospital of Eastern Ontario, 401 Smyth Rd, K1H 8 L1 Ottawa, ON, Canada
| | - Valerie Hastings
- Department of Genetics, Children's Hospital of Eastern Ontario, 401 Smyth Rd, K1H 8 L1 Ottawa, ON, Canada
| | - Pedro Pinto
- Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
| | - Marc Tischkowitz
- Program in Cancer Genetics, Departments of Oncology and Human Genetics, Gerald Bronfman Centre for Clinical Research in Oncology, McGill University, Montreal, QC, Canada ; Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada ; Department of Medical Genetics, University of Cambridge, Cambridge, UK
| | - Eva Tomiak
- Department of Genetics, Children's Hospital of Eastern Ontario, 401 Smyth Rd, K1H 8 L1 Ottawa, ON, Canada ; Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - William D Foulkes
- Program in Cancer Genetics, Departments of Oncology and Human Genetics, Gerald Bronfman Centre for Clinical Research in Oncology, McGill University, Montreal, QC, Canada ; Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada ; Department of Medical Genetics, McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
13
|
Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Zhang L, Norton L, Hudis C, Klein RJ, Kauff ND, Robson M, Stadler ZK, Haber DA, Lipkin SM, Friedman E, Foulkes WD, Altshuler D, Vijai J, Offit K. Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. J Clin Oncol 2014; 34:e61-7. [PMID: 24982446 DOI: 10.1200/jco.2013.50.0272] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
| | | | | | - Yael Laitman
- Chaim Sheba Medical Center, Tel-Hashomer, and Tel Aviv University, Tel-Aviv, Israel
| | - Luca Cavallone
- Lady Davis Institute, Jewish General Hospital, Montreal, Québec, Canada
| | - Lily Offit
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Tinu Thomas
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Sohela Shah
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | - Ebun Otegbeye
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Liying Zhang
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Larry Norton
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | - Noah D Kauff
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Mark Robson
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Daniel A Haber
- Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA; and Howard Hughes Medical Institute, Chevy Chase, MD
| | | | - Eitan Friedman
- Chaim Sheba Medical Center, Tel-Hashomer, and Tel Aviv University, Tel-Aviv, Israel
| | - William D Foulkes
- Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Québec, Canada
| | - David Altshuler
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA
| | - Joseph Vijai
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Kenneth Offit
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
14
|
Witkowski L, Lalonde E, Zhang J, Albrecht S, Hamel N, Cavallone L, May ST, Nicholson JC, Coleman N, Murray MJ, Tauber PF, Huntsman DG, Schönberger S, Yandell D, Hasselblatt M, Tischkowitz MD, Majewski J, Foulkes WD. Familial rhabdoid tumour 'avant la lettre
'-from pathology review to exome sequencing and back again. J Pathol 2013; 231:35-43. [DOI: 10.1002/path.4225] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2013] [Revised: 06/06/2013] [Accepted: 06/10/2013] [Indexed: 01/08/2023]
Affiliation(s)
- Leora Witkowski
- Program in Cancer Genetics, Department of Oncology and Human Genetics; McGill University, Montreal; Quebec Canada
- Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; McGill University, Montreal; Quebec Canada
- Department of Human Genetics; McGill University, Montreal; Quebec Canada
| | - Emilie Lalonde
- Department of Human Genetics; McGill University, Montreal; Quebec Canada
- McGill University and Genome Quebec Innovation Center, Montreal; Quebec Canada
| | - Jian Zhang
- Department of Human Genetics; McGill University, Montreal; Quebec Canada
- McGill University and Genome Quebec Innovation Center, Montreal; Quebec Canada
| | - Steffen Albrecht
- Department of Pathology, Montreal Children's Hospital; McGill University Health Centre, Montreal; Quebec Canada
| | - Nancy Hamel
- Program in Cancer Genetics, Department of Oncology and Human Genetics; McGill University, Montreal; Quebec Canada
- Research Institute; McGill University Health Centre, Montreal; Quebec Canada
| | - Luca Cavallone
- Program in Cancer Genetics, Department of Oncology and Human Genetics; McGill University, Montreal; Quebec Canada
- Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; McGill University, Montreal; Quebec Canada
| | - Sandra Thompson May
- Vermont Cancer Center; University of Vermont College of Medicine; Burlington VT USA
| | - James C Nicholson
- Department of Paediatric Oncology and Haematology; Cambridge University Hospitals NHS Foundation Trust; Cambridge UK
| | | | - Matthew J Murray
- Department of Paediatric Oncology and Haematology; Cambridge University Hospitals NHS Foundation Trust; Cambridge UK
- Department of Pathology; University of Cambridge; UK
| | - Peter F Tauber
- Department of Obstetrics and Gynecology; St. Mary's Hospital; Siegen Germany
| | - David G Huntsman
- British Columbia Cancer Research Center; British Columbia Cancer Agency, Vancouver; BC Canada
- Genetic Pathology Evaluation Center of the Departments of Pathology of Vancouver General Hospital; the Center for Translational and Applied Genomics, and Pathology and Laboratory Medicine; Vancouver BC Canada
| | - Stefan Schönberger
- Department of Paediatric Haematology and Oncology; University Children's Hospital; University of Bonn Germany
| | - David Yandell
- Vermont Cancer Center; University of Vermont College of Medicine; Burlington VT USA
| | | | | | - Jacek Majewski
- Department of Human Genetics; McGill University, Montreal; Quebec Canada
- McGill University and Genome Quebec Innovation Center, Montreal; Quebec Canada
| | - William D Foulkes
- Program in Cancer Genetics, Department of Oncology and Human Genetics; McGill University, Montreal; Quebec Canada
- Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital; McGill University, Montreal; Quebec Canada
- Department of Human Genetics; McGill University, Montreal; Quebec Canada
- Research Institute; McGill University Health Centre, Montreal; Quebec Canada
| |
Collapse
|
15
|
Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Shah S, Rau-Murthy R, Manschreck C, Otegbeye E, Corines M, Kauff ND, Klein RJ, Robson ME, Stadler ZK, Friedman E, Foulkes W, Vijai J, Offit K. Genome sequencing of multiple primary tumors to reveal underlying germline cancer susceptibility. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.1552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1552 Background: Apart from germline mutations in BRCA1 and BRCA2, the basis for genetic susceptibility to breast and ovarian cancer is heterogeneous, and can necessitate sequential or multiplex genetic testing. In addition, examination of germline DNA alone may not be conclusive. Information regarding both primary and secondary genetic events can be obtained from genomic analysis of tumors in conjunction with germline DNA. Methods: To determine the underlying cause of multiple primary malignancies in an Ashkenazi Jewish individual, whole genome sequencing was performed on DNA from the patient’s germline, invasive ductal carcinoma of the breast, and ovarian high-grade serous carcinoma. After identifying a structural variant of interest in this patient, germline DNA of 1846 Ashkenazi Jewish individuals who had a personal history of either breast, pancreatic, or ovarian cancer or a history of both breast and/or ovarian cancer and a similar family history, were screened using a TaqMan copy number assay or a specific PCR breakpoint assay to determine if this structural variant is a founder mutation. Results: A novel germline complex structural variant of PALB2 creating a 3790 base-pair deletion encompassing exon 11 associated with a 68 base-pair insertion was identified and confirmed by Sanger sequencing and a TaqMan copy number assay. The germline deletion was retained in both tumors. In addition, both tumors acquired second hits that led to inactivation of the wild-type allele of PALB2. The germline PALB2 structural variant was not identified in any of the additional 1846 Ashkenazi Jewish individuals genotyped. Conclusions: Whole genome sequencing of multiple primary tumors enabled identification and characterization of a novel germline structural variant in PALB2 as the basis for the individual’s susceptibility to breast and ovarian cancer. The variant does not appear to be a founder mutation in Ashkenazim.
Collapse
Affiliation(s)
- Kasmintan A. Schrader
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Kelly Lynn Stratton
- Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Rajmohan Murali
- Department of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Yael Laitman
- The Oncogenetics unit and the Institute of Genetics, The Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - Luca Cavallone
- Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
| | - Lily Offit
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Yong Hannah Wen
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Sohela Shah
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Rohini Rau-Murthy
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Christopher Manschreck
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Ebunoluwa Otegbeye
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Marina Corines
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Noah D. Kauff
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Robert J. Klein
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | - Eitan Friedman
- The Oncogenetics unit and the Institute of Genetics, The Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - William Foulkes
- Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
| | - Joseph Vijai
- Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Kenneth Offit
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
16
|
Légaré S, Cavallone L, Mamo A, Chabot C, Keilty D, Magliocco A, Klimowicz A, Tonin P, Basik M. Abstract LB-47: SPEN is a novel candidate tumor suppressor gene that regulates response to tamoxifen in estrogen receptor positive breast cancers. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-lb-47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The majority of breast cancers are hormone-responsive and are treated with anti-estrogens, such as tamoxifen. However, most of the 30 and 50% of estrogen receptor positive (ER+) patients that initially respond to tamoxifen eventually become resistant to the drug. Although there are several mechanisms responsible for resistance of breast cancers to tamoxifen, no predictive biomarkers for tamoxifen resistance are in clinical use besides the estrogen receptor (ER) and the progesterone receptors (PR). Using a novel integrative genomic method based on the discovery of nonsense mutations in deleted chromosomal fragments, we identified a nonsense mutation in the SPEN gene in the T47D breast cancer cell line. SPEN is a transcriptional repressor of the estrogen-signaling pathway, which is recruited to estrogen-responsive elements upon activation of the ER. We found 4 somatic mutations (2 nonsense and 2 missense) in 23 breast tumors showing loss of heterozygosity at the SPEN locus. Moreover, tissue microarrays showed that SPEN was frequently over-expressed in the nucleus of normal breast epithelial cells, but in only 10% of breast tumor cells, suggesting that inactivation of SPEN in breast cancer contributes to disease progression. In vitro, overexpression of SPEN in the T47D breast cancer cell line, in which SPEN is mutated and endogenous levels of the protein are very low, resulted in significantly decreased cell proliferation and anchorage-independent growth, decreased PR expression as well as increased sensitivity to tamoxifen. Remarkably, tamoxifen treatment induced 5-fold higher levels of apoptosis in SPEN-overexpressing compared to control T47D cells. In addition, using a tissue microarray of 100 tumor samples from ER+ breast cancer patients treated with tamoxifen only, we found that patients whose tumors express high levels of SPEN had a much better prognosis than patients whose tumors express low or no levels of the protein. To identify transcriptional targets of SPEN besides the PR, we performed gene expression profiling on a panel of breast cancer cell lines in which SPEN was either overexpressed or knocked-down. We found an inverse relationship between SPEN and Apolipoprotein D (APOD) expression, suggesting that SPEN potently repressed transcription of the APOD gene. APOD encodes a glycoprotein from the lipocalin family, which can chelate multiple molecules including progesterone, arachidonic acid as well as tamoxifen itself. Hence, our analysis shows that the loss or mutation of SPEN in ER+ breast cancers has the potential to affect tumor growth as well as sensitivity to tamoxifen, in part through upregulation of APOD expression. Together, our results highlight the role of SPEN as a novel putative tumor suppressor gene in breast cancer and suggest that SPEN is a candidate predictive biomarker of tamoxifen resistance in ER+ breast cancer patients.
Citation Format: Stéphanie Légaré, Luca Cavallone, Aline Mamo, Catherine Chabot, Dana Keilty, Anthony Magliocco, Alexander Klimowicz, Patricia Tonin, Mark Basik. SPEN is a novel candidate tumor suppressor gene that regulates response to tamoxifen in estrogen receptor positive breast cancers. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-47. doi:10.1158/1538-7445.AM2013-LB-47
Collapse
Affiliation(s)
| | - Luca Cavallone
- 2Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
| | - Aline Mamo
- 2Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
| | - Catherine Chabot
- 2Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
| | - Dana Keilty
- 1McGill University, Montreal, Quebec, Canada
| | | | | | | | - Mark Basik
- 1McGill University, Montreal, Quebec, Canada
| |
Collapse
|
17
|
Zhang J, Shi Y, Lalonde E, Li L, Cavallone L, Ferenczy A, Gotlieb WH, Foulkes WD, Majewski J. Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. BMC Cancer 2013; 13:146. [PMID: 23522120 PMCID: PMC3614563 DOI: 10.1186/1471-2407-13-146] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2012] [Accepted: 03/13/2013] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Ovarian carcinoma is a common, and often deadly, gynecological cancer. Mutations in BRCA1 and BRCA2 genes are present in at least a fifth of patients. Uncovering other genes that become mutated subsequent to BRCA1/BRCA2 inactivation during cancer development will be helpful for more effective treatments. METHODS We performed exome sequencing on the blood, primary tumor, omental metastasis and recurrence following therapy with carboplatin and paclitaxel, from a patient carrying a BRCA1 S1841R mutation. RESULTS We observed loss of heterozygosity in the BRCA1 mutation in the primary and subsequent tumors, and somatic mutations in the TP53 and NF1 genes were identified, suggesting their role along with BRCA1 driving the tumor development. Notably, we show that exome sequencing is effective in detecting large chromosomal rearrangements such as deletions and amplifications in cancer. We found that a large deletion was present in the three tumors in the regions containing BRCA1, TP53, and NF1 mutations, and an amplification in the regions containing MYC. We did not observe the emergence of any new mutations among tumors from diagnosis to relapse after chemotherapy, suggesting that mutations already present in the primary tumor contributed to metastases and chemotherapy resistance. CONCLUSIONS Our findings suggest that exome sequencing of matched samples from one patient is a powerful method of detecting somatic mutations and prioritizing their potential role in the development of the disease.
Collapse
Affiliation(s)
- Jian Zhang
- Department of Human Genetics, McGill University, Montreal, QC, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK. Erratum: Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med 2011. [DOI: 10.1038/nm1111-1521a] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
19
|
Ha KCH, Lalonde E, Li L, Cavallone L, Natrajan R, Lambros MB, Mitsopoulos C, Hakas J, Kozarewa I, Fenwick K, Lord CJ, Ashworth A, Vincent-Salomon A, Basik M, Reis-Filho JS, Majewski J, Foulkes WD. Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. BMC Med Genomics 2011; 4:75. [PMID: 22032724 PMCID: PMC3227591 DOI: 10.1186/1755-8794-4-75] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2011] [Accepted: 10/27/2011] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Gene fusions arising from chromosomal translocations have been implicated in cancer. However, the role of gene fusions in BRCA1-related breast cancers is not well understood. Mutations in BRCA1 are associated with an increased risk for breast cancer (up to 80% lifetime risk) and ovarian cancer (up to 50%). We sought to identify putative gene fusions in the transcriptomes of these cancers using high-throughput RNA sequencing (RNA-Seq). METHODS We used Illumina sequencing technology to sequence the transcriptomes of five BRCA1-mutated breast cancer cell lines, three BRCA1-mutated primary tumors, two secretory breast cancer primary tumors and one non-tumorigenic breast epithelial cell line. Using a bioinformatics approach, our initial attempt at discovering putative gene fusions relied on analyzing single-end reads and identifying reads that aligned across exons of two different genes. Subsequently, latter samples were sequenced with paired-end reads and at longer cycles (producing longer reads). We then refined our approach by identifying misaligned paired reads, which may flank a putative gene fusion junction. RESULTS As a proof of concept, we were able to identify two previously characterized gene fusions in our samples using both single-end and paired-end approaches. In addition, we identified three novel in-frame fusions, but none were recurrent. Two of the candidates, WWC1-ADRBK2 in HCC3153 cell line and ADNP-C20orf132 in a primary tumor, were confirmed by Sanger sequencing and RT-PCR. RNA-Seq expression profiling of these two fusions showed a distinct overexpression of the 3' partner genes, suggesting that its expression may be under the control of the 5' partner gene's regulatory elements. CONCLUSIONS In this study, we used both single-end and paired-end sequencing strategies to discover gene fusions in breast cancer transcriptomes with BRCA1 mutations. We found that the use of paired-end reads is an effective tool for transcriptome profiling of gene fusions. Our findings suggest that while gene fusions are present in some BRCA1-mutated breast cancers, they are infrequent and not recurrent. However, private fusions may still be valuable as potential patient-specific biomarkers for diagnosis and treatment.
Collapse
Affiliation(s)
- Kevin C H Ha
- Department of Human Genetics, McGill University, Montreal, Quebec, H3A 1B1, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med 2011; 17:1275-82. [PMID: 21946536 DOI: 10.1038/nm.2459] [Citation(s) in RCA: 175] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2010] [Accepted: 08/03/2011] [Indexed: 12/13/2022]
Abstract
BRCA1, a well-known tumor suppressor with multiple interacting partners, is predicted to have diverse biological functions. However, so far its only well-established role is in the repair of damaged DNA and cell cycle regulation. In this regard, the etiopathological study of low-penetrant variants of BRCA1 provides an opportunity to uncover its other physiologically important functions. Using this rationale, we studied the R1699Q variant of BRCA1, a potentially moderate-risk variant, and found that it does not impair DNA damage repair but abrogates the repression of microRNA-155 (miR-155), a bona fide oncomir. Mechanistically, we found that BRCA1 epigenetically represses miR-155 expression via its association with HDAC2, which deacetylates histones H2A and H3 on the miR-155 promoter. We show that overexpression of miR-155 accelerates but the knockdown of miR-155 attenuates the growth of tumor cell lines in vivo. Our findings demonstrate a new mode of tumor suppression by BRCA1 and suggest that miR-155 is a potential therapeutic target for BRCA1-deficient tumors.
Collapse
Affiliation(s)
- Suhwan Chang
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Chabot C, Mamo A, Cavallone L, Tuzmen S, Hassan S, Edgren H, Ferrario C, Aleynikova O, Przybytkowska E, Malcolm K, Kallioniemi O, Tonin P, Mousses S, Basik M. Abstract 4023: ARID1A is a candidate tumor suppressor gene in breast cancer. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-4023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Tumor suppressor genes (TSGs) have been classically defined as genes whose loss of function in tumor cells contributes to the formation and/or maintenance of the tumor phenotype. Typically but not always, tumors neutralize both alleles of TSGs by deleting one copy and mutating the other. One molecular strategy to discover potential tumor suppressor gene candidates involves the “re-expression” of RNA transcripts containing nonsense mutations by inhibition of the nonsense-mediated RNA decay (NMD) process. Combining NMD inhibition with array CGH has lead to the genome-wide identification of genes with biallelic inactivation (involving nonsense mutations on one allele and loss of the second allele) in prostate cancer cell lines and identified EphB2 as a novel candidate TSG in prostate cancer. Using such a strategy in 5 breast cancer cell lines, we identified ARID1A as a NMD target in the T47D breast cancer cell line. ARID1A encodes a human homologue of yeast SWI1, which contains a DNA-binding motif (AT-rich interactive domain, ARID) and is an integral member of the hSWI/SNF complex, an ATP-dependent chromatin-remodeling multiple-subunit enzyme. Mutations in the ARID1A gene were recently reported to be present in 50% of clear cell tumors of the ovary. We found the ARID1A gene contains a nonsense mutation in exon 9, which introduces a premature stop codon, changing Q944 to a stop codon in the T47D breast cancer cell line. Although we did not find any somatic mutations in breast tumors, we show that low ARID1A RNA expression or low ARID1A nuclear protein expression is associated with more aggressive breast cancer phenotypes in 2 independent cohorts of over 200 breast cancers each. We also found that low or absent ARID1A nuclear expression becomes more prevalent during the later stages of breast tumor progression. Finally, we found that ARID1A re-expression in the breast cancer cell line in which it is mutated results in significant inhibition of colony formation in soft agar. These results suggest that the ARID1A gene may be a candidate tumor suppressor gene in breast cancer, and that it warrants further investigation as potential diagnostic and therapeutic marker in breast cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4023. doi:10.1158/1538-7445.AM2011-4023
Collapse
Affiliation(s)
| | - Aline Mamo
- 1Segal Cancer Center, Montréal, Quebec, Canada
| | - Luca Cavallone
- 2Dept Human Genetics, McGill University, Montréal, Quebec, Canada
| | - Sukru Tuzmen
- 3Translational Genomics Research Institute, Phoenix, AZ
| | | | - Henrik Edgren
- 4Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | | | - Olga Aleynikova
- 5Dept Pathology, Jewish General Hospital, Montréal, Quebec, Canada
| | | | | | - Olli Kallioniemi
- 4Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Patricia Tonin
- 2Dept Human Genetics, McGill University, Montréal, Quebec, Canada
| | - Spyro Mousses
- 3Translational Genomics Research Institute, Phoenix, AZ
| | - Mark Basik
- 1Segal Cancer Center, Montréal, Quebec, Canada
| |
Collapse
|
22
|
Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, Licastro F, Colonna-Romano G, Lio D, Candore G, Caruso C. Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. ACTA ACUST UNITED AC 2008; 59:155-63. [PMID: 18675847 DOI: 10.1016/j.brainresrev.2008.07.003] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2008] [Revised: 07/04/2008] [Accepted: 07/08/2008] [Indexed: 11/26/2022]
Abstract
The pro-inflammatory cytokine interleukin(IL)-1beta is a main component in inflammatory pathways and is overexpressed in the brain of Alzheimer's disease (AD) patients. Several studies report associations between IL-1beta polymorphisms and AD, but findings from different studies are controversial. Our aim was to verify the correlation between the single nucleotide polymorphisms (SNPs) of the IL-1beta, at sites -511 and +3953, and AD by meta-analysis. Computerized bibliographic searches of PUBMED and AlzGene database (http://www.alzgene.org) were supplemented with manual searches of reference lists. There is evidence for association between IL-1beta +3953 SNP and AD, with an OR=1.60 (95% C.I.: 1.16-2.22; Z=2.83 p=0.005) for TT genotype. No significant difference in genotype distribution of the IL-1beta -511 SNP in AD was obtained, but high between-study heterogeneity was found. To reduce heterogeneity, subgroup analyses were performed using, as stratifying variables, characteristics of the population under study (age, gender, type of AD diagnosis, Mini Mental State Examination of the controls) and characteristics related to the study design (statistical power of individual studies). The frequency of the IL-1beta -511 TT genotype resulted significantly higher than other genotypes only when the Caucasian studies with the highest statistical power were included in the subgroup analysis (OR=1.32; 95% C.I.: 1.03-1.69; p=0.03), with no evidence of between-study heterogeneity. Our data support an association between the TT genotype of IL-1beta +3953 SNP and AD, and suggest a possible association of the -511 TT genotype. Unreplicability of the results seems to be due mainly to the lack of statistical power of the individual studies.
Collapse
Affiliation(s)
- Danilo Di Bona
- Istituto di Biomedicina ed Immunologia Molecolare (IBIM), CNR, Palermo Università di Palermo, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Cardelli M, Cavallone L, Marchegiani F, Oliveri F, Dato S, Montesanto A, Lescai F, Lisa R, De Benedictis G, Franceschi C. A genetic-demographic approach reveals male-specific association between survival and tumor necrosis factor (A/G)-308 polymorphism. J Gerontol A Biol Sci Med Sci 2008; 63:454-60. [PMID: 18511747 DOI: 10.1093/gerona/63.5.454] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The (A/G)-308 polymorphism of the tumor necrosis factor alpha gene (TNF) is associated with age-related diseases, but its influence on longevity is controversial. We genotyped for this polymorphism 747 Italian volunteers (401 women and 346 men, age 19-110 years). By applying a genetic-demographic (GD) approach we found that, in men, the survival function of allele A carriers is lower than that of noncarriers at all the ages (p =.044). After defining (by exploiting again demographic information) three age classes, we found that the frequency of men carrying the A allele decreases with age (p =.019), thus confirming the GD analysis results. The same analyses gave negative results in women. Therefore, allele A has a detrimental effect on life expectancy, and this effect is specific to men. A haplotype analysis carried out in men by screening the TNFa, TNFc, and TNFe microsatellite polymorphisms (spanning about 20 kb) confirmed the association of the TNF region with life expectancy.
Collapse
Affiliation(s)
- Maurizio Cardelli
- Department of Gerontological Research, Italian National Research Center on Aging, Ancona, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 2008; 8:96. [PMID: 18402691 PMCID: PMC2329651 DOI: 10.1186/1471-2407-8-96] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2007] [Accepted: 04/10/2008] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The TP53 polymorphisms Arg72Pro (Ex4+199 G>C) and Ins16 (IVS3+24 ins16) have been proposed to modify risk of breast cancer associated with germline BRCA1 and BRCA2 mutations. Allele frequencies of these polymorphisms were investigated to determine if they modify risk in BRCA mutation carriers in breast cancer cases drawn from French Canadian cancer families, a population shown to exhibit strong founder effects. METHODS The frequencies of the TP53 alleles, genotypes and haplotypes of 157 index breast cancer cases comprised of 42 BRCA1 mutation carriers, 57 BRCA2 mutation carriers, and 58 BRCA mutation-negative cases, where each case was drawn from independently ascertained families were compared. The effect of TP53 variants on the age of diagnosis was also investigated for these groups. The TP53 polymorphisms were also investigated in 112 women of French Canadian descent with no personal history of cancer. RESULTS The BRCA mutation-positive groups had the highest frequency of homozygous carriers of the 72Pro allele compared with mutation-negative group. The TP53 polymorphisms exhibited linkage disequilibrium (p < 0.001), where the 72Arg and Ins16minus alleles occurred in strong disequilibrium. The highest frequency of carriers of Ins16minus-72Arg haplotype occurred in the BRCA mutation-negative groups. The BRCA1 mutation carriers homozygous for the 72Pro allele had the youngest ages of diagnosis of breast cancer. However none of these observations were statistically significant. In contrast, the BRCA2 mutation carriers homozygous for the 72Pro allele had a significantly older age of diagnosis of breast cancer (p = 0.018). Moreover, in this group, the mean age of diagnosis of breast cancer in carriers of the Ins16minus-72Arg haplotype was significantly younger than that of the individuals who did not this carry this haplotype (p = 0.009). CONCLUSION We observed no significant association of breast cancer risk with TP53 genetic variants based on BRCA1/2 mutation carrier status. Although the small sample size did not permit analysis of all possible haplotypes, we observed that BRCA2 mutation carriers harboring the Ins16minus-72Arg haplotype had a significantly younger mean age of diagnosis of breast cancer. These observations suggest that investigations in a larger French Canadian sample are warranted to further elucidate the effects of TP53 variants on age of diagnosis of breast cancer among BRCA1 and BRCA2 mutation carriers.
Collapse
Affiliation(s)
- Luca Cavallone
- Department of Human Genetics, McGill University, Montreal, Canada
| | | | | | | | | | | | | |
Collapse
|
25
|
Antonicelli R, Olivieri F, Cavallone L, Spazzafumo L, Bonafè M, Marchegiani F, Cardelli M, Galeazzi R, Giovagnetti S, Perna GP, Franceschi C. Tumor necrosis factor-alpha gene -308G>A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coron Artery Dis 2006; 16:489-93. [PMID: 16319659 DOI: 10.1097/00019501-200512000-00006] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES As is well known, acute myocardial infarction presents two electrocardiogram (EKG) patterns, ST-elevation (STEMI) and no ST-elevation (NSTEMI), characterized by different coronary artery thrombotic occlusion. Growing evidence shows that inflammation plays a central role in the pathogenesis of acute myocardial infarction. Among the factors that promote inflammation and arterial thrombosis, one of the most important is the proinflammatory cytokine tumor necrosis factor-alpha. The expression of this cytokine is modulated by a polymorphism located at nucleotide -308 of tumor necrosis factor-alpha promoter gene. The objective of our study is to verify whether tumor necrosis factor-alpha -308 polymorphism is associated with risk of acute myocardial infarction (STEMI and NSTEMI) or with biochemical myocardial ischemia markers, such as troponin I, creatine kinase-MB, lactate dehydrogenase and myoglobin. METHODS We analyzed tumor necrosis factor-alpha -308 polymorphism in a total of 603 study participants: 293 elderly patients affected by acute myocardial infarction (STEMI and NSTEMI) and 310 healthy controls. RESULTS We found that individuals carrying the tumor necrosis factor-alpha -308 AG+AA genotypes are significantly more represented among acute myocardial infarction patients affected by STEMI than among NSTEMI patients (OR = 1.86, 95% CI 1.08-3.21, p = 0.027) and healthy controls (OR = 1.64, 95% CI 1.03-2.64, p = 0.046). Furthermore, the patients carrying tumor necrosis factor-alpha -308 AG+AA genotypes displayed significant increased levels of biochemical myocardial ischemia markers. CONCLUSIONS Our study shows a significant association between the tumor necrosis factor-alpha -308 polymorphism and the occurrence of STEMI, and suggests that the tumor necrosis factor-alpha -308 polymorphism could play a role in the pathogenesis of cardiac ischemic damage, AA+AG genotype carrier individuals being likely to be affected by more severe ischemic damage than the rest of the population.
Collapse
Affiliation(s)
- Roberto Antonicelli
- Center of Molecular Biology, Department of Cardiology-CCU and Center of Statistics, Italian National Research Centers on Aging (I.N.R.C.A.), Ancona, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Olivieri F, Antonicelli R, Cardelli M, Marchegiani F, Cavallone L, Mocchegiani E, Franceschi C. Genetic polymorphisms of inflammatory cytokines and myocardial infarction in the elderly. Mech Ageing Dev 2006; 127:552-9. [PMID: 16516951 DOI: 10.1016/j.mad.2006.01.013] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2005] [Revised: 10/07/2005] [Accepted: 01/16/2006] [Indexed: 01/28/2023]
Abstract
Cardiovascular diseases (CVD), such as myocardial infarction (MI), are major causes of disability and mortality in the elderly. The increasing burden of CVD in ageing industrialized populations requires intensive research in order to improve preventive and therapeutic strategies especially in old people and if possible slow the processes of cardiovascular disease generation and progression. Ageing is accompanied by an age-dependent up-regulation of the inflammatory response, due to chronic antigenic stress stimulation, which potentially triggers the onset of inflammatory diseases, especially CVD. However, the exact mechanisms are still poorly understood. Since CVD are caused by interactions between genetic and environmental factors, a possible approach to their prevention is to identify the potential genetic component of inflammatory cardiovascular risk factors, providing the basis for personalized lifestyle modification and improved pharmacological therapy. Some common gene polymorphisms associated with high production of inflammatory molecules have been associated with atherosclerosis. Therefore, controlling inflammation might play a protective role against CVD, especially in ageing. Although a large number of studies of pro- and anti-inflammatory gene variants in association with CVD and MI exists, the emerging data are quite conflicting and do not provide definitive evidence for a role of these polymorphisms in the pathogenesis of MI. In this paper we review the evidence for a possible role of genetic polymorphisms of the most important inflammatory cytokines (IL-6, TNF-alpha, IL-10) and immune receptors (CD14 receptor and TLR-4) in modulating the incidence or the prognosis of MI, with a special focus in ageing population.
Collapse
Affiliation(s)
- Fabiola Olivieri
- Centre of Genetic and Molecular Biology, Research Department, Italian National Research Centre on Aging, Ancona, Italy.
| | | | | | | | | | | | | |
Collapse
|
27
|
Marchegiani F, Marra M, Spazzafumo L, James RW, Boemi M, Olivieri F, Cardelli M, Cavallone L, Bonfigli AR, Franceschi C. Paraoxonase Activity and Genotype Predispose to Successful Aging. J Gerontol A Biol Sci Med Sci 2006; 61:541-6. [PMID: 16799134 DOI: 10.1093/gerona/61.6.541] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The paraoxonase 1 codon 192 R allele has been previously reported to have a role in successful aging. The relationship between PON1 genotypes, enzymatic activity, and mass concentration was evaluated in a group of 229 participants from 22 to 104 years of age, focusing our attention on nonagenarian/centenarian participants. We found a genetic control for paraoxonase activity that is maintained throughout life, also in the nonagenarians/centenarians. This activity decreases significantly during aging and shows different mean values among R and M carriers, where R+ and M- carriers have the significant highest paraoxonase activity. Results from the multinomial regression logistic model show that paraoxonase activity as well as R+ and M- carriers contribute significantly to the explanation of the longevity phenotype. In conclusion, we show that genetic variability at the PON1 locus is related to paraoxonase activity throughout life, and suggest that both parameters affect survival at extreme advanced age.
Collapse
|
28
|
Cardelli M, Marchegiani F, Cavallone L, Olivieri F, Giovagnetti S, Mugianesi E, Moresi R, Lisa R, Franceschi C. A Polymorphism of the YTHDF2 Gene (1p35) Located in an Alu-Rich Genomic Domain Is Associated With Human Longevity. J Gerontol A Biol Sci Med Sci 2006; 61:547-56. [PMID: 16799135 DOI: 10.1093/gerona/61.6.547] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The uneven distribution of Alu repetitive elements in the human genome is related to specific functional properties of genomic regions. We report the identification of a locus associated with human longevity in one of the chromosomal regions with the highest density of Alu elements, in 1p35. The locus, corresponding to a (TG)n microsatellite in the YTHDF2 gene, was identified by characterizing an "anonymous" marker detectable through inter-Alu fingerprinting, which previously evidenced an increased homozygosity in centenarians. After genotyping 412 participants of different ages, including 137 centenarians, we confirmed the increased homozygosity in centenarians at this locus, and observed a concomitantly increased frequency of the most frequent allele and the corresponding homozygous genotype. Remarkably, the same genotype was associated with increased YTHDF2 messenger RNA levels in immortalized lymphocytes. Finally, YTHDF2 messenger RNA resulted to be mainly expressed in testis and placenta. The data suggest a possible role of this locus in human longevity.
Collapse
Affiliation(s)
- Maurizio Cardelli
- Department of Gerontological Research, Italian National Research Center on Aging (I.N.R.C.A), Via Birarelli 8, 60100 Ancona, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Antonicelli R, Olivieri F, Bonafè M, Cavallone L, Spazzafumo L, Marchegiani F, Cardelli M, Recanatini A, Testarmata P, Boemi M, Parati G, Franceschi C. The interleukin-6 -174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol 2005; 103:266-71. [PMID: 16098388 DOI: 10.1016/j.ijcard.2004.08.064] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2004] [Revised: 07/15/2004] [Accepted: 08/07/2004] [Indexed: 11/15/2022]
Abstract
BACKGROUND Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) are key mediators of inflammation and their increased plasma levels are associated with acute coronary syndrome (ACS). Polymorphisms in the promoter region of IL-6 (-174 G>C) and TNF-alpha (-308 G>A) demonstrated to affect gene expression were analyzed to test their predictive power for cardiovascular death over one year follow-up in elderly male ACS patients. METHODS We assessed the IL-6 -174 G>C polymorphism and TNF-alpha -308 G>A polymorphism in 139 consecutive elderly male patients affected by an ACS, such as ST-Elevation (STEMI), No ST-Elevation (NSTEMI) Myocardial Infarction and Unstable Angina. The presence of well known risk factors for Coronary Heart Diseases (CHD) were also assessed in all ACS patients. Survival rate was assessed after one year follow-up. RESULTS We found that IL-6 -174 G>C polymorphism is an independent predictor of cardiovascular death after an ACS in male patients. In particular ACS patients carrying the IL-6 -174 C- (GG) genotypes showed a marked increase in one year follow-up mortality rate (HR=3.89, 95% CI 1.71-8.86, p=0.001). Moreover CRP serum levels > or = 5.5 mg/dl (HR= 3.79, 95% CI 1.71-8.42, p=0.001), a history of CHD (HR=2.96, 95% CI 1.22-7.20, p=0.016) and the absence of statins treatment (HR=3.27, 95% CI 1.17-9.18, p=0.021), significantly increased one year risk of death in male ACS patients. CONCLUSIONS These data suggest that IL-6 -174 G>C polymorphism can be added to other clinical markers in order to identify a subgroup of elderly ACS male patients at higher risk of death.
Collapse
Affiliation(s)
- Roberto Antonicelli
- Department of Cardiology, Center of Molecular Biology, Center of Statistics and Diabetologic Unit, Italian National Research Centers on Aging (INRCA), Via della Montagnola, 81, 60121 Ancona, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Lio D, Candore G, Crivello A, Scola L, Colonna-Romano G, Cavallone L, Hoffmann E, Caruso M, Licastro F, Caldarera CM, Branzi A, Franceschi C, Caruso C. Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet 2005; 41:790-4. [PMID: 15466015 PMCID: PMC1735604 DOI: 10.1136/jmg.2004.019885] [Citation(s) in RCA: 103] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
31
|
Franceschi C, Olivieri F, Marchegiani F, Cardelli M, Cavallone L, Capri M, Salvioli S, Valensin S, De Benedictis G, Di Iorio A, Caruso C, Paolisso G, Monti D. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev 2005; 126:351-61. [PMID: 15621218 DOI: 10.1016/j.mad.2004.08.028] [Citation(s) in RCA: 145] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
In this paper, we review data of recent literature on the distribution in centenarians of candidate germ-line polymorphisms that likely affect the individual chance to reach the extreme limit of human life. On the basis of previous observations on the immunology, endocrinology and cellular biology of centenarians we focused on genes that regulate immune responses and inflammation (IL-6, IL-1 cluster, IL-10), genes involved in the insulin/IGF-I signalling pathway and genes that counteract oxidative stress (PON1). On the whole, data indicate that polymorphisms of these genes likely contribute to human longevity, in accord with observations emerging from a variety of animal models, and suggest that a common core of master genes and metabolic pathways are responsible for aging and longevity across animal species. Moreover, in the concern of our plan to discover new genetic factors related to longevity, we explored the possibility to by-pass the need of an a-priori choice of candidate genes, extending the search to genes and genomic regions of still unknown function. Alu sequences may be considered as good markers of highly variable and potentially unstable loci in functionally important genomic regions. We extensively screened Alu-rich genomic sites and found a new genomic region associated with longevity.
Collapse
|
32
|
Abstract
Cancer rates increase sharply with age in both sexes, and the majority of cases of cancer occur in patients over the age of 65 years. However, the incidence and mortality for cancer level off around 85-90 years of age, followed by a plateau, or even a decline in the last decades of life. Therefore, it seems reasonable to conclude that centenarians are endowed with a peculiar resistance to cancer. Tumor progression is a complex process that depends on interactions between tumor and host cells. One aspect of the host response, the inflammatory response, is of particular interest because it includes the release of proinflammatory cytokines, some of which may promote tumor growth and hence influence survival. Data in the literature reviewed in this paper suggest that some kind of solid tumors are affected by regulatory cytokine genotypes. In particular proinflammatory genotypes characterized by a low IL-10 producer or a high IL-6 producer seem to be associated with a worse clinical outcome. On the other hand, recent evidence has linked IL-10 and IL-6 cytokine polymorphisms to longevity. In fact, those individuals who are genetically predisposed to produce high levels of IL-6 have a reduced capacity to reach the extreme limits of human life, whereas the high IL-10-producer genotype is increased among centenarians. This opposite effect of IL-6 and IL-10 common gene polymorphisms in cancer and longevity is intriguing. These data prompt considerations of the role that antagonistic pleiotropy plays in disease and in longevity. Inflammatory genotypes may be both friends and enemies. In fact, they are an important and necessary part of the normal host responses to pathogens, but the overproduction of inflammatory cytokines might cause immune-inflammatory diseases and eventually death. In fact, our immune system has evolved to control pathogens, so proinflammatory responses are likely to be evolutionarily programmed to resist fatal infections, and a high IL-6 or a low IL-10 production is associated with increased resistance to pathogens. However, decreased level of IL-6 or increased level of IL-10 might better control inflammatory responses and cancer development. These conditions might result in an increased chance of long-life survival in an environment with a reduced antigen (i.e., pathogen) load.
Collapse
Affiliation(s)
- Calogero Caruso
- Gruppo di Studio sull'Immunosenescenza, Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, Italy
| | | | | | | |
Collapse
|
33
|
Carrieri G, Marzi E, Olivieri F, Marchegiani F, Cavallone L, Cardelli M, Giovagnetti S, Stecconi R, Molendini C, Trapassi C, De Benedictis G, Kletsas D, Franceschi C. The G/C915 polymorphism of transforming growth factor beta1 is associated with human longevity: a study in Italian centenarians. Aging Cell 2004; 3:443-8. [PMID: 15569360 DOI: 10.1111/j.1474-9728.2004.00129.x] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Sequence variations in a variety of pro- or anti-inflammatory cytokine genes have been found to influence successful aging and longevity. Because of the role played by the transforming growth factor beta1 (TGF-beta1) cytokine in inflammation and regulation of immune responses, the variability of the TGF-beta1 gene may affect longevity by playing a role in inflamm-aging. Two polymorphisms, G/A -800 and C/T -509, located in the 5' region, and two missense polymorphisms, T/C 869 and G/C 915 which change (Leu > Pro)10 and (Arg > Pro)25, respectively, located in the signal peptide, were analysed in 419 subjects from Northern and Central Italy, including 172 centenarians and 247 younger controls. In addition, the effects of the TGF-beta1 genetic variability on plasma levels of the biologically active form (naturally processed) of this cytokine were studied in 143 randomly selected subjects, including 73 centenarians. Significant differences were found at the +915 site as far as the C allele and GC genotype were concerned, both of them being lower in centenarians than in young controls (P=0.034 and 0.028, respectively), but none of the other tested genetic variants was significantly different between centenarians and controls. Moreover, a particular haplotype combination (G -800/C -509/C 869/C 915) was notably lower in centenarians than in younger individuals (P=0.007). Finally, active TGF-beta1 plasma levels were significantly increased in the elderly group, but no relationship with TGF-beta1 genotypes was observed. These results suggest that, at least in this population, the variability of the TGF-beta1 gene influences longevity and that the age-related increase in plasma levels of active TGF-beta1 seems not to be genetically regulated.
Collapse
|
34
|
Listì F, Candore G, Lio D, Cavallone L, Colonna-Romano G, Caruso M, Hoffmann E, Caruso C. Association between platelet endothelial cellular adhesion molecule 1 (PECAM-1/CD31) polymorphisms and acute myocardial infarction: a study in patients from Sicily. ACTA ACUST UNITED AC 2004; 31:175-8. [PMID: 15265022 DOI: 10.1111/j.1365-2370.2004.00464.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Adhesion of circulating cells to the arterial surface is among the first detectable events in atherogenesis. Cellular adhesion molecules, expressed by the vascular endothelium and by circulating leucocytes, mediate cell recruitment and their transendothelial migration. Platelet endothelial cellular adhesion molecule 1 (PECAM-1/CD31), involved in this migration, has been associated with the developmental course of atherosclerosis. A few studies have investigated an association between coronary heart disease and single nucleotide polymorphisms (SNPs) located in functionally important domains of the PECAM-1/CD31 gene. In particular, Ser563Asn and Gly670Arg SNPs have been described as susceptibility factors involved in acute myocardial infarction (AMI) in the Japanese male population. To confirm these observations, we studied 96 male patients (mean age 40 years; age range 20-46) affected by AMI and 118 healthy male controls (mean age 38 years, age range: 20-55), and analysed for the following PECAM-1/CD31 SNPs: Val125Leu, Asn563Ser and Gly670Arg. The frequency of the Gly670Arg polymorphism was significantly higher in patients with AMI (58.9% vs. 48.3%; P = 0.019), whereas the frequencies of the other two SNPs (Leu125Val and Ser563Asn) were not significantly different between patients and controls. By comparing the observed number of 670Arg/Arg genotypes in the patients with the expected number, calculated from the allele frequency in a healthy population, a significance of P = 0.02 (odds ratio, 2.04; 95% CI: 1.1-3.7) was obtained, supporting a recessive model of inheritance. Hence, the differences between patients and controls are significant, but relatively small. However, as AMI is a multifactorial disease, any single mutation will only provide a small or modest contribution to the risk, which also depends on environmental interaction. All in all, we believe that the results of the present study would add support to the role of pro/anti-inflammatory genotypes in determining susceptibility or resistance to immune-inflammatory diseases, including atherosclerosis.
Collapse
Affiliation(s)
- F Listì
- Gruppo di Studio sull'Immunosenescenza, Dipartiento di Biopatologia e Metodologie Biomediche, Università di Palermo, Italy
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Giampieri C, Centurelli M, Bonafè M, Olivieri F, Cardelli M, Marchegiani F, Cavallone L, Giovagnetti S, Mugianesi E, Carrieri G, Lisa R, Cenerelli S, Testa R, Boemi M, Petropoulou C, Gonos ES, Franceschi C. A novel mitochondrial DNA-like sequence insertion polymorphism in Intron I of the FOXO1A gene. Gene 2004; 327:215-9. [PMID: 14980718 DOI: 10.1016/j.gene.2003.11.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2003] [Revised: 10/03/2003] [Accepted: 11/07/2003] [Indexed: 10/26/2022]
Abstract
The human forkhead box O1A (FOXO1A) gene belongs to the human forkhead gene family and acts downstream of the human insulin signalling pathway. In this study, polymorphisms of the Intron I of FOXO1A gene were studied in Italian healthy people and insulin resistant subjects. No significant association between the germ-line variability in the Intron I of FOXO1A and insulin resistance was observed. Interestingly, during the study, a new 39-bp sequence insertion polymorphism in Intron I of FOXO1A gene was described. The polymorphism was found to co-segregate in a co-dominant Mendelian fashion and to be present in an ethnically distinct population (Greeks). A BLAST search showed that the sequence shares 100% identity with a mtDNA (mitochondrial DNA) sequence coding for the ATP synthase 8 (ATPase8) and ATP synthase 6 (ATPase6) genes. Hence, FOXO1A Intron I is a polymorphic nuclear region involved in the exchange of DNA material between mitochondrial and genomic DNA, which is a well-established mechanism of evolutionary change in eukaryotes.
Collapse
Affiliation(s)
- Claudia Giampieri
- Department of Research and Diabetology Unit, Italian National Research Centers on Ageing, Via Birarelli 8, Ancona 60124, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Licastro F, Grimaldi LME, Bonafè M, Martina C, Olivieri F, Cavallone L, Giovanietti S, Masliah E, Franceschi C. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003; 24:921-6. [PMID: 12928051 DOI: 10.1016/s0197-4580(03)00013-7] [Citation(s) in RCA: 114] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Two different polymorphic regions of the interleukin-6 (IL-6) gene were investigated in patients with Alzheimer's disease (AD) and non-demented controls. The -174 C allele in the promoter region of IL-6 gene was over-represented in AD patients compared to controls and significantly increased the risk of AD. Moreover, the -174 CC genotype was associated with a high risk of the disease in women. The D allele of a variable number of tandem repeat (VNTR) was in strong linkage disequilibrium with the -174 C allele and slightly increased AD risk. On the other hand, the frequency of the VNTR C allele was decreased in patients with AD and was negatively associated with the risk of developing AD. Both the -174 CC and VNTR DD genotypes were also associated with increased IL-6 levels in the blood and brain from AD. These findings suggest that IL-6 may play a multifaceted role in AD by affecting the turnover of the cytokine.
Collapse
Affiliation(s)
- Federico Licastro
- Department of Experimental Pathology, University of Bologna, Via S. Giacomo 14, 40126 Bologna, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Cavallone L, Bonafè M, Olivieri F, Cardelli M, Marchegiani F, Giovagnetti S, Di Stasio G, Giampieri C, Mugianesi E, Stecconi R, Sciacca F, Grimaldi LM, De Benedictis G, Lio D, Caruso C, Franceschi C. The role of IL-1 gene cluster in longevity: a study in Italian population. Mech Ageing Dev 2003; 124:533-8. [PMID: 12714264 DOI: 10.1016/s0047-6374(03)00033-2] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In this study, we analysed the polymorphic variants of IL-1alpha (C-T transition at position -889), IL-1beta (C-T transition at position -511) and IL-1 receptor antagonist (Ra) (86-bp repeated sequence in intron 2) in 1131 subjects (453 females and 678 males) from Northern and Central Italy, including 134 centenarians, to evaluate whether IL-1 cluster alleles might be differently represented in people selected for longevity. In addition, IL-1Ra and IL-1beta plasma levels were quantified by ELISA in 130 randomly selected subjects. No significant differences in the genotype and allele frequency distributions were observed between young, elderly and centenarian subjects. IL-1Ra plasma levels showed an age-related increase, whereas IL-1beta plasma levels did not show any detectable age-related trend. Neither IL-1Ra nor IL-1beta plasma levels showed any relationship with genotypes of the three IL-1 genes. These results suggest that no one particular polymorphism in the IL-1 gene cluster yields an advantage for survival in the last decades of life, and that the age-related increase in plasma levels of IL-1Ra seems not to be genetically regulated but a likely safeguard mechanism to buffer the age-associated increased inflammatory state.
Collapse
Affiliation(s)
- Luca Cavallone
- Direzione Scientifica, Italian National Research Center on Aging, Villa Gusso, Via S. Margherita, n. 5 60121, Ancona, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafé M, Cavallone L, Marchegiani F, Olivieri F, Franceschi C, Caruso C. Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP. J Med Genet 2003; 40:296-9. [PMID: 12676903 PMCID: PMC1735442 DOI: 10.1136/jmg.40.4.296] [Citation(s) in RCA: 144] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Olivieri F, Bonafè M, Giovagnetti S, Stecconi R, Cardelli M, Cavallone L, Spazzafumo L, Marchegiani F, Carrieri G, Mugianesi E, Giampieri C, Centurelli M, Moresi R, Tesei S, Lisa R, Viticchi C, Falsetti L, Salvioli S, Franceschi C. In vitro IL-6 production by EBV-immortalized B lymphocytes from young and elderly people genotyped for -174 C/G polymorphism in IL-6 gene: a model to study the genetic basis of inflamm-aging. Mech Ageing Dev 2003; 124:549-53. [PMID: 12714266 DOI: 10.1016/s0047-6374(03)00035-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In the present investigation we analysed Interleukin 6 (IL-6) in vitro production by Epstein-Barr virus (EBV)-immortalized B lymphocytes established from 43 subjects, 15 young people and 28 elderly people, including 18 centenarians, after 3, 6, 9, 24, 48 and 72 h of culture. The subjects were genotypized for the C to G transition at nucleotide -174 of IL-6 gene promoter (-174 C/G) and were classified as C allele carriers (C+) and non-carriers (C-). We found that: (i) the interindividual difference in in vitro IL-6 production was wider in elderly individuals in respect to young individuals, leading to different coefficient of variation in the two groups; (ii) the -174 C/G polymorphism had an age-related effect on IL-6 in vitro production. Only among C- people, cells from elderly subjects produced significant higher level of IL-6 than cells from young subjects. These data are consistent with our previous results regarding the IL-6 serum levels in a large group of people of different age, including centenarians. Thus, the EBV-immortalized B lymphocytes can be considered a useful in vitro model for studying the genetic control of IL-6 production and its changes with age.
Collapse
Affiliation(s)
- Fabiola Olivieri
- Italian National Research Centers on Aging (I.N.R.C.A.), Via S. Margherita, n. 5, 60121, Ancona, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Bonafè M, Marchegiani F, Cardelli M, Olivieri F, Cavallone L, Giovagnetti S, Pieri C, Marra M, Antonicelli R, Troiano L, Gueresi P, Passeri G, Berardelli M, Paolisso G, Barbieri M, Tesei S, Lisa R, De Benedictis G, Franceschi C. Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur J Hum Genet 2002; 10:292-6. [PMID: 12082503 DOI: 10.1038/sj.ejhg.5200806] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2001] [Revised: 03/08/2002] [Accepted: 03/20/2002] [Indexed: 11/09/2022] Open
Abstract
Human Paraoxonase (PON1) is a High-Density Lipoprotein (HDL)-associated esterase that hydrolyses lipo-peroxides. PON1 has recently attracted attention as a protective factor against oxidative modification of LDL and may therefore play an important role in the prevention of the atherosclerotic process. Two polymorphisms have been extensively studied: a Leucine (L allele) to Methionine (M allele) substitution at codon 55, and a Glutamine (A allele) to Arginine (B allele) substitution at codon 192. We have examined these two aminoacidic changes in 579 people aged 20 to 65 years old, and 308 centenarians. We found that the percentage of carriers of the B allele at codon 192 (B+ individuals) is higher in centenarians than in controls (0.539 vs 0.447), moreover we found that among the B+ individuals, the phenomenon was due to an increase of people carrying M alleles at codon 55 locus. In conclusion, we propose that genetic variability at PON1 locus affects survival at extreme advanced age.
Collapse
|
41
|
Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafè M, Cavallone L, Franceschi C, Caruso C. Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun 2002; 3:30-3. [PMID: 11857058 DOI: 10.1038/sj.gene.6363827] [Citation(s) in RCA: 174] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2001] [Revised: 10/16/2001] [Accepted: 10/16/2001] [Indexed: 12/16/2022]
Abstract
Ageing is characterized by a pro-inflammatory status, which could contribute to the onset of major age-related diseases. Thus, genetic variations in pro- or anti-inflammatory cytokines might influence successful ageing and longevity. IL-10 is an appropriate candidate because it exerts powerful inhibitory effects on pro-inflammatory function. IL-10 production is controlled by several polymorphic elements in the 5' flanking region of IL-10 gene on 1q32 locus, involving alleles at two microsatellite regions and several polymorphisms in promoter region. We analysed in 190 Italian centenarians (>99 years old, 159 women and 31 men) and in 260 <60 years old control subjects (99 women and 161 men), matched for geographical distribution, genotype frequencies for -1082G-->A, -819C-->T and -592C-->A IL-10 proximal promoter gene biallelic polymorphisms by sequence specific probes. -1082G homozygous genotype was increased in centenarian men (P < 0.025) but not in centenarian women. No difference was found between centenarians and control subjects regarding the other two polymorphisms. The presence of -1082GG genotype, suggested to be associated with high IL-10 production, significantly increases the possibility to reach the extreme limit of human lifespan in men. Together with previous data on other polymorphic loci (Tyrosine Hydroxylase, mitochondrial DNA, IL-6, haemochromatosis, IFN-gamma), this finding points out that that gender is a major variable in the genetics of longevity, suggesting that men and women follow different strategies to reach longevity. Concerning the biological significance of this association, we have not searched for functional proves that IL-10 is involved. Thus, we should conclude that our data only suggest that a marker on 1q32 genomic region may be involved in successful ageing in man. However, recent data on IL-6 and IFN-gamma genes suggest that longevity is negatively associated with genotypes coding for a pro-inflammatory profile. Thus, it is intriguing that the possession of -1082G genotype, suggested to be associated with IL-10 high production, is significantly increased in centenarians.
Collapse
Affiliation(s)
- D Lio
- Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, Palermo, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Olivieri F, Bonafè M, Cavallone L, Giovagnetti S, Marchegiani F, Cardelli M, Mugianesi E, Giampieri C, Moresi R, Stecconi R, Lisa R, Franceschi C. The -174 C/G locus affects in vitro/in vivo IL-6 production during aging. Exp Gerontol 2002; 37:309-14. [PMID: 11772517 DOI: 10.1016/s0531-5565(01)00197-8] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
IL-6 in vitro production, as well as the serum/plasma concentration of the cytokine, increase with age. In the present investigation, a total of 62 individuals (31 males and 31 females), aged from 29 to 93 years of age (mean age of males: 60.4 years; mean age of females: 59.4 years) were assessed for IL-6 plasma concentration, and for IL-6 in vitro production, using supernatants of 4h cultured adherent peripheral blood mononuclear cells (aPBMC). The subjects were examined for a C to G transition at nucleotide -174 of the IL-6 gene promoter (-174 C/G locus), and were classified as C allele carriers (C+) or non-carriers (C-). We found that: (i) aPBMC from C+ individuals produced smaller amounts of IL-6 in vitro than C- individuals; (ii) IL-6 production by aPBMC increased with age in C+ but not in C- subjects; (iii) there was no correlation between IL-6 plasma levels and in vitro IL-6 production by aPBMC; (iv) IL-6 C+ individuals had lower plasma levels than C- individuals, and this phenomenon was significant only in men. On the whole our data indicate that the production of IL-6 is genetically controlled and age- and gender-dependent.
Collapse
Affiliation(s)
- Fabiola Olivieri
- Direzione Scientifica Italian National Research Centers on Aging (INRCA), Via S. Margherita, n.5, 60121 Ancona, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Bonafè M, Olivieri F, Cavallone L, Giovagnetti S, Mayegiani F, Cardelli M, Pieri C, Marra M, Antonicelli R, Lisa R, Rizzo MR, Paolisso G, Monti D, Franceschi C. A gender--dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001. [PMID: 11500818 DOI: 10.1002/1521-4141(200108)31:8<2357::aid-immu2357>3.0.co;2-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Current literature indicates that elevated IL-6 serum levels are associated with diseases, disability and mortality in the elderly. In this paper, we studied the IL-6 promoter genetic variability at -174 C/G locus and its effect on IL-6 serum levels in a total of 700 people from 60 to 110 years of age, including 323 centenarians. We found that the proportion of homozygotes for the G allele at -174 locus decreases in centenarian males, but not in centenarian females. Moreover, we found that, only among males, homozygotes for the G allele at -174 locus have higher IL-6 serum levels in comparison with carriers of the C allele. On the whole, our data suggest that those individuals who are genetically predisposed to produce high levels of IL-6 during aging, i.e. -174 locus GG homozygous men, are disadvantaged for longevity.
Collapse
Affiliation(s)
- M Bonafè
- Department of Experimental Pathology, Bologna University, Bologna, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Bonafè M, Olivieri F, Cavallone L, Giovagnetti S, Mayegiani F, Cardelli M, Pieri C, Marra M, Antonicelli R, Lisa R, Rizzo MR, Paolisso G, Monti D, Franceschi C. A gender--dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001; 31:2357-61. [PMID: 11500818 DOI: 10.1002/1521-4141(200108)31:8<2357::aid-immu2357>3.0.co;2-x] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Current literature indicates that elevated IL-6 serum levels are associated with diseases, disability and mortality in the elderly. In this paper, we studied the IL-6 promoter genetic variability at -174 C/G locus and its effect on IL-6 serum levels in a total of 700 people from 60 to 110 years of age, including 323 centenarians. We found that the proportion of homozygotes for the G allele at -174 locus decreases in centenarian males, but not in centenarian females. Moreover, we found that, only among males, homozygotes for the G allele at -174 locus have higher IL-6 serum levels in comparison with carriers of the C allele. On the whole, our data suggest that those individuals who are genetically predisposed to produce high levels of IL-6 during aging, i.e. -174 locus GG homozygous men, are disadvantaged for longevity.
Collapse
Affiliation(s)
- M Bonafè
- Department of Experimental Pathology, Bologna University, Bologna, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Bonafè M, Cardelli M, Marchegiani F, Cavallone L, Giovagnetti S, Olivieri F, Lisa R, Pieri C, Franceschi C. Increase of homozygosity in centenarians revealed by a new inter-Alu PCR technique. Exp Gerontol 2001; 36:1063-73. [PMID: 11404051 DOI: 10.1016/s0531-5565(01)00112-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In the present study a novel inter-Alu PCR technique that allows one to detect inter-individual differences in the genomic regions flanked by Alu repetitive sequences was developed. Two primers complementary to sequences present in different Alu repeats and marked with two different fluorochromes were used in the same PCR reaction, and the PCR products were separated and analyzed by capillary electrophoresis using an automatic sequencer. The method is highly reliable, and three patterns of peaks (QM376-400, QM780-790 and QM480) appeared to be representative for germ-line polymorphisms, as suggested by the results obtained in nine couples of monozygotic twins and four three-generation families. The frequency of these polymorphic peaks was studied in two different age groups (100 young subjects and 69 centenarians). In two out of the three regions (QM376-400 and QM480) a significant increase in homozygote genotypes frequency was observed in centenarians. These counterintuitive results suggest that increased homozygosity contributes to human longevity. This novel inter-Alu PCR approach could represent a valuable tool to identify longevity-associated DNA sequences interspersed throughout human genome, without making any a priori assumption about their nature and function.
Collapse
Affiliation(s)
- M Bonafè
- Department of Experimental Pathology, University of Bologna, Bologna, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Licastro F, Pedrini S, Bonafe M, Grimaldi LM, Olivieri F, Cavallone L, Giovannetti S, Franceschi C. Polymorphisms of the IL-6 gene increase the risk for late onset Alzheimer's disease and affected IL-6 plasma levels. Neurobiol Aging 2000. [DOI: 10.1016/s0197-4580(00)82845-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
47
|
Franceschi C, Motta L, Valensin S, Rapisarda R, Franzone A, Berardelli M, Motta M, Monti D, Bonafè M, Ferrucci L, Deiana L, Pes GM, Carru C, Desole MS, Barbi C, Sartoni G, Gemelli C, Lescai F, Olivieri F, Marchegiani F, Cardelli M, Cavallone L, Gueresi P, Cossarizza A, Troiano L, Pini G, Sansoni P, Passeri G, Lisa R, Spazzafumo L, Amadio L, Giunta S, Stecconi R, Morresi R, Viticchi C, Mattace R, De Benedictis G, Baggio G. Do men and women follow different trajectories to reach extreme longevity? Italian Multicenter Study on Centenarians (IMUSCE). Aging (Milano) 2000; 12:77-84. [PMID: 10902049 DOI: 10.1007/bf03339894] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Gender accounts for important differences in the incidence and prevalence of a variety of age-related diseases. Considering people of far advanced age, demographic data document a clear-cut prevalence of females compared to males, suggesting that sex-specific mortality rates follow different trajectories during aging. In the present investigation, we report data from a nationwide study on Italian centenarians (a total of 1162 subjects), and from two studies on centenarians living in two distinct zones of Italy, i.e., the island of Sardinia (a total of 222 subjects) and the Mantova province (Northern Italy) (a total of 43 subjects). The female/male ratio was about 2:1 in Sardinia, 4:1 in the whole of Italy, and about 7:1 in the Mantova province. Thus, a complex interaction of environmental, historical and genetic factors, differently characterizing the various parts of Italy, likely plays an important role in determining the gender-specific probability of achieving longevity. Gender differences in the health status of centenarians are also reported, and an innovative score method to classify long-lived people in different health categories, according to clinical and functional parameters, is proposed. Our data indicate that not only is this selected group of people, as a whole, highly heterogeneous, but also that a marked gender difference exists, since male centenarians are less heterogeneous and more healthy than female centenarians. Immunological factors regarding the age-related increase in pro-inflammatory status, and the frequency of HLA ancestral haplotypes also show gender differences that likely contribute to the different strategies that men and women seem to follow to achieve longevity. Concerning the different impact of genetic factors on the probability of reaching the extreme limits of the human life-span, emerging evidence (regarding mtDNA haplogroups, Thyrosine Hydroxilase, and IL-6 genes) suggests that female longevity is less dependent on genetics than male longevity, and that female centenarians likely exploited a healthier life-style and more favorable environmental conditions, owing to gender-specific cultural and anthropological characteristics of the Italian society in the last 100 years.
Collapse
Affiliation(s)
- C Franceschi
- Department of Experimental Pathology, University of Bologna.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Bonafè M, Olivieri F, Mari D, Baggio G, Mattace R, Berardelli M, Sansoni P, De Benedictis G, De Luca M, Marchegiani F, Cavallone L, Cardelli M, Giovagnetti S, Ferrucci L, Amadio L, Lisa R, Tucci MG, Troiano L, Pini G, Gueresi P, Morellini M, Sorbi S, Passeri G, Barbi C, Valensin S, Monti D, Deiana L, Pes GM, Carru C, Franceschi C. P53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia. Am J Hum Genet 1999; 65:1782-5. [PMID: 10577935 PMCID: PMC1288391 DOI: 10.1086/302664] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Affiliation(s)
- Massimiliano Bonafè
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Fabiola Olivieri
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Daniela Mari
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Giovannella Baggio
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Rosario Mattace
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Maurizio Berardelli
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Paolo Sansoni
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Giovanna De Benedictis
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Maria De Luca
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Francesca Marchegiani
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Luca Cavallone
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Maurizio Cardelli
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Simona Giovagnetti
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Luigi Ferrucci
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Loredana Amadio
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Rosamaria Lisa
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Maria Giovanna Tucci
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Leonarda Troiano
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Gabriella Pini
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Paola Gueresi
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Marina Morellini
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Sandro Sorbi
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Giovanni Passeri
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Cristiana Barbi
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Silvana Valensin
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Daniela Monti
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Luca Deiana
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Giovanni Mario Pes
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Ciriaco Carru
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| | - Claudio Franceschi
- Departments
of Experimental Pathology and Statistical
Science, University of Bologna, Bologna; Italian National
Research Centers on Aging, Ancona and Florence; Institute of
Internal Medicine, I.R.C.C.S. Maggiore Hospital, University of Milan,
Milan; Chair of Geriatrics and Gerontology and
Institute of Clinical Biochemistry, University of Sassari,
Sassari, Italy; Chair of Geriatrics, University of Reggio
Calabria, Catanzaro, Italy; Institute of Internal Medicine
and Medical Therapy, University of Parma, Parma,
Italy; Department of Cell Biology, University of Calabria,
Rende, Italy; Department of Biomedical Sciences, University
of Modena, Modena, Italy; Department of Experimental
Medicine, Section of Genetics, University “La Sapienza,” Rome;
and Department of Neurological and Psychiatric Sciences
and Institute of General Pathology, University of
Florence, Florence
| |
Collapse
|
49
|
Iapichino G, Radrizzani D, Veschi G, Biondi A, Cambisano M, Cavallone L, Colombo A, Pasetti G, Codazzi D, Russo R. [Body, muscle, and visceral nitrogen balance in catabolic patients. Modification with metabolic treatment]. Minerva Anestesiol 1993; 59:79-86. [PMID: 8515856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
In sixteen severely catabolic patients, two different nutritional treatments with the same nitrogen input (0.30 gN.kg-1.die-1) but with a different caloric support: 30 kcal.kg-1.die-1 foe group A and 15 kcal.kg-1.die-1 for group B were infused. Body nitrogen balance (BN), muscle nitrogen balance (BNm) and, calculated as a difference of the two, visceral nitrogen balance were measured in every patient on basal day and on the second day of total parenteral nutrition. Both nutritional treatment reduced the catabolic state in the same amount: this was confirmed by a less negative body BN and by the reduced excretion of 3-MEH and amino acidic catabolic markers. Otherwise in the other compartments the treatments showed different effects: the metabolic support was more reduced by treatment A than it was by B, supplying to visceral compartment a lower nitrogen amount: the nitrogen dismission from muscle compartment, available for visceral tissues, is greater with treatment B than with treatment A. In conclusion, even if both treatments show the same effect on body nitrogen balance, they penalize either one of the examined compartment or the other. To avoid this problem, the study and the use of tissue-specific nutrients are desiderable. Tissue-specific solutions may warrant the balance among body compartment without any further increase of the nitrogen rate.
Collapse
Affiliation(s)
- G Iapichino
- Reparto di Rianimazione E. Vecla, IRCCS Ospedale Maggiore di Milano
| | | | | | | | | | | | | | | | | | | |
Collapse
|